# NHS BLOOD AND TRANSPLANT NATIONAL LIVER OFFERING SCHEME FIFTY-FOUR MONTH REVIEW

# SUMMARY

# 1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity.
- 1.2. It should be noted that this report may not include all data due to delays in reporting.
- 1.3. Updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in Figure 9B.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and the changes to the DBD offering scheme ceased on 9 July 2020 when named patient offering recommenced. This period is excluded from part of the liver offering section.
- 1.5. The estimates used to calculate the Transplant Benefit Score (TBS) will be updated at the beginning of October 2022 and were outside this report.

# 2. DATA AND METHODS

2.1. **Table S1** shows the time period and inclusion and exclusion criteria for the aspects of the offering scheme examined in this report. NHS Group 2 registrations and transplants were excluded throughout the report along with registrations, offers and transplants for intestinal patients not requiring a liver. Super-urgent and elective registrations were included in all aspects apart from the transplant list activity section as were adult and paediatric registrations and transplants. All full year time periods are 20 March to 19 March.

1

Table S1	Inclusion and exclusion criteria for the a	spects of NLOS examined in thi	is report
Section	Time period	Inclusions	Exclusions
Registration activity	<ul> <li>20 March 2017 to 19 March 2018 (Year prior, N=1169)</li> <li>20 March 2018 to 19 September 2022 (fifty-four months post, N=5283)</li> </ul>	New active/suspended registrations	<ul> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> </ul>
One and three month post- registration outcome	<ul> <li>20 December 2016 to 19 December 2017 (Year prior, N=945)</li> <li>20 March 2018 to 19 December 2021 (fifty-one months post, N=4076)</li> </ul>	<ul> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
Six months post- registration outcome	<ul> <li>20 September 2016 to 19 September 2017 (<i>Year prior</i>, N=906)</li> <li>20 March 2018 to 19 September 2021 (<i>forty-two post</i>, N=3825)</li> </ul>	<ul> <li>Active and suspended</li> <li>Adult elective liver and liver/kidney registrations</li> </ul>	<ul> <li>Dublin registrations</li> <li>NHS Group 2 registrations</li> <li>Intestinal registrations</li> </ul>
Liver offering	<ul> <li>Year prior, N=1914 (962 DBD and 952 DCD)</li> <li><i>Fifty-four months post</i>, N=7871 (3975 DBD and 3896 DCD)</li> </ul>	<ul> <li>UK deceased donors whose liver was offered for transplantation</li> <li>Offers to Dublin for super- urgent patients</li> </ul>	<ul> <li>Intestinal offers regardless of whether patients required a liver</li> <li>Offers declined due to the patient accepting previously offered liver</li> <li>Offers to Dublin for elective patients</li> </ul>
Transplant activity	<ul> <li>Year prior, N=1017 (819 DBD and 198 DCD)</li> <li><i>Fifty-four months post</i>, N=3981 (3177 DBD and 804 DCD))</li> </ul>	UK transplants	<ul> <li>Transplants performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>
Ninety-day post- transplant survival	<ul> <li>20 March 2017 to 19 March 2018 (N=579 for DBD and 183 for DCD)</li> <li>20 March 2018 to 19 June 2022 (N=2051 for DBD and 650 for DCD)</li> </ul>	UK adult elective liver and liver/kidney transplants	<ul> <li>Transplants performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>
One-year post- transplant survival	<ul> <li>20 March 2017 to 19 March 2018 (N=579 for DBD and 183 for DCD)</li> <li>20 March 2018 to 19 September 2021 (N=1759 for DBD and 526 for DCD)</li> </ul>	UK adult elective liver and liver/kidney transplants	<ul> <li>Transplants performed at Dublin</li> <li>Intestinal transplants for patients not requiring a liver</li> <li>NHS Group 2 transplants</li> </ul>

# 3. RESULTS

#### **REGISTRATION ACTIVITY**

- 3.1. There were 5283 new NHS Group 1 liver registrations in the UK in the first fifty-four months of the scheme. (**Table 1**)
- 3.2. The proportion of elective liver registrations decreased from 88.5% to 86.5% between the 2017/2018 and 2022/2023. The proportion of adult elective registrations with CLD has increased from 71% in 2017/2018 to 75% in 2022/2023 but the proportion of HCC registrations (including HCC downstaging) has decreased by 3%. The number of new variant syndrome registrations has decreased from 83 in 2017/2018 to 63 in 2021/2022. (Table 3)
- 3.3. Ninety-three percent of the new adult elective registrations in 2022/2023 were for first graft compared with 91% in 2017/2018 (**Table 4**)
- 3.4. The median age of new adult elective registrations increased from 55 in 2017/2018 to 56.5 in 2022/2023. (Table 5)

#### POST-REGISTRATION OUTCOME

- 3.5. There were 4076 adult elective registrations in the subset of patients registered in the first fifty-four months post-NLOS. The proportion of registrations who received a transplant within three months of registration ranged from 39% to 52% across the yearly time periods post NLOS. (Table 6)
- 3.6. The proportion of patients who either died on the list or were removed due to condition deterioration in the first three months ranged from 3% to 5% in the time periods post NLOS compared to 6% in the time period prior. In the six-month registration outcome time periods, the proportion of patients who either died on the list or were removed due to condition deterioration ranged from 4% to 9% in the time periods post NLOS compared to 8% in the time period prior. (Figures 6 and B4)

## LIVER OFFERING

- 3.7. Overall, 3975 DBD livers and 3896 DCD livers were offered in the first fifty-four months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 90% in the 54 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 43% for the 54 month post and 32% in the year prior to NLOS. (Table 8)
- 3.8. Figures 9a and 9b in the main paper show the number of DBD livers offered during the first fiftyfour months at each stage of the liver offering pathway. Livers offered during COVID are included in Figure 9a but excluded at the elective stage of Figure 9b. Six hundred and three livers were either accepted and transplanted or declined and not offered on prior to the elective section of the offering pathway.

- 3.9. Of the 3174 DBD livers offered to the elective section that were not offered only to paediatric centres and not offered during the first wave of COVID-19 in 2020, 2849 (90%) were allocated to the elective CLD/HCC pathway and 325 (10%) were randomly allocated to the variant syndrome pathway which is consistent with the percentages used in the probabilistic prioritisation of the elective list.
- 3.10. One thousand, five hundred and twenty-nine livers (not accepted by higher tiers) offered to named elective CLD/HCC were accepted and transplanted while 124 livers offered to the named elective variant syndrome pathway were accepted and transplanted.
- 3.11. One thousand, three hundred and thirty-nine livers declined by all stages were fast-tracked and 526 were accepted and transplanted.
- 3.12. 6435 (35%) of the 18357 offers made in the first 54 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 4487 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.13. The number of named patient offers per donor ranged between 1 and 10 with a median of one named patient offers per donor. The number of named offers per patient ranged between 1 and 27 with a median of two offers per patient. Forty-one patients at 7 centres were offered 11 or more livers in the fifty-four month time period (17 were offered 11 livers, 9 were offered 12 livers, 4 were offered 13 livers, 4 were offered 14 livers, 1 was offered 15 livers, 2 were offered 17, 1 was offered 21 and 3 were offered 27 livers).

#### TRANSPLANT ACTIVITY

- 3.14. The proportion of super-urgent transplants performed in 2022/2023 post NLOS time period increased from the proportion performed in the time period prior to NLOS implementation (11% to 15%). There were 108 DBD super-urgent transplants pre NLOS 2017/2018 and 58 DBD super-urgent transplants in the first 6 months of 2022/2023. However it should be noted that the number of super-urgent transplants performed between March and September 2022 has increased for both adult and paediatric patients. (Table 14)
- 3.15. One hundred and forty of the 3676 adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the transplant section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients.
- 3.16. For DBD transplants, there was evidence of a statistically significant association between time period and age group (p=0.0006), disease group (p=0.002), transplant centre (p=0.045), zonal (p<0.0001), type of patient (p<0.0001) and blood group compatibility (p<0.0001). (Table 15).</p>

- 3.17. For DCD transplants, there was evidence of a statistically significant association between time period and disease group (p=0.0077), transplant centre (p<0.0001) and type of patient (p=0.039). There was no significance for blood group compatibility (p=0.47), similarly with association for age group (p=0.22) and zonal transplants (p=0.86). (Table 16).</li>
- 3.18. There was a statistically significant difference in cold ischaemia time for adult elective DBD transplants across the time periods of interest (p=0.002). However, this may be due to the inclusion of periods of machine perfusion which is not currently collected on the liver transplant record form. (**Figure 15**)
- 3.19. There was no significant difference in ninety-day DBD and DCD patient survival (p-value=0.15 and 0.11 respectively). (**Figure 19**). There was no significant difference at a 5% significance level in ninety-day transplant survival for either DBD or DCD transplants (p-value=0.59 and 0.54 respectfully). (**Figure 20**).
- 3.20. There was no significant difference in one-year DBD and DCD patient survival (p-value=0.38 and 0.52 respectively). (Figure 21). There was no significant difference at a 5% significance level in one-year transplant survival for either DBD or DCD transplants (p-value=0.68 and 0.72 respectively). (Figure 22).

Rhiannon Taylor, Maria Jacobs and Suzie Phillips Statistics and Clinical Research

October 2022

# NHS BLOOD AND TRANSPLANT NATIONAL LIVER OFFERING SCHEME FIFTY-FOUR MONTH REVIEW

## 1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity. All full year time periods are 20 March to 19 March.
- 1.2. It should also be noted that this report may not include all data due for the first fifty-four months due to delays in reporting.
- 1.3. The updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in Figure 9B.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and NLOS resumed on 9 July 2020.
- 1.5. Birmingham, Royal Free, Kings College and Cambridge temporarily closed for all adult transplants in December 2020/January 2021. Royal Free and Birmingham temporarily transferred some of their clinically urgent patients to other transplant centres who were open. Transplant centres reviewed their transplant lists in January 2021 and formally suspended non-urgent patients. Offering to named clinically urgent patients continued and centres could consider livers for nonurgent patients if declined for all clinically urgent patients.
- 1.6. All transplant centres other than Birmingham formally reactivated all non-urgent CLD and HCC patients on the 6<sup>th</sup> April 2021 while variant syndrome patients and patients at Birmingham were reactivated in late April 2021.

6

- Birmingham closed for all DCD offers in January 2021 with Newcastle and Leeds receiving Birminghams zonal and linked offers on a rota basis. Birmingham reopened for DCD offers in late April 2021.
- 1.8. The parameter estimates and baseline survivor functions used to calculate the TBS were updated on 4 October 2022 and are not included in this report.

# 2. DATA AND METHODS

# 2.1. REGISTRATION ACTIVITY AND POST-REGISTRATION OUTCOME

- 2.1.1. Data on 6452 new active/suspended NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 September 2022 were obtained from the UK Transplant Registry on 27 September 2022. Patients registered in Dublin or as NHS Group 2 were excluded as such elective patients would only be offered a liver if all UK transplant centres declined the offer.
- 2.1.2. One and three month registration outcome was examined for registrations either between 20 December 2016 and 19 December 2017 (N=945) or between 20 March 2018 and 19 June 2022 (N=4076).
- 2.1.3. Six month registration outcome was also examined for a subset registered either between 20 September 2016 and 19 September 2017 (N=906) or between 20 March 2018 and 19 March 2022 (N=3828).

## 2.2. LIVER OFFERING

2.2.1. Data on 9785 deceased donors (4937 DBD and 4848 DCD) from the UK whose liver was offered for transplantation between 20 March 2017 and 19 September 2022 were obtained from the UK Transplant Registry on 7 October 2022. Intestinal offers were excluded regardless of whether they required a liver or not. The data was split into five year periods.

## 2.3. TRANSPLANT ACTIVITY AND POST-TRANSPLANT SURVIVAL

2.3.1. Data on 4998 deceased donor liver transplants (3996 DBD and 1002 DCD) performed in the UK between 20 March 2017 and 19 September 2022 were also obtained from the UK Transplant Registry on 30 September 2022. Intestinal transplants involving the liver were included.

# 3. RESULTS

#### 3.1. REGISTRATION ACTIVITY - OVERALL

3.1.1. **Figure 1** shows the number of new NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 September 2022 by quarter and urgency status while **Table 1** compares the twelve months pre the introduction of NLOS and the fifty-four months post the introduction of NLOS. There was no statistically significant association between the time of registration and registration type (Chi-squared p-value =0.06). It should be noted that there was an increase in the number of paediatric acute liver failure patients in the first two quarters of 2022.




Table 1Urgency status by time period for all NHS Group 1 liver registrations in the UK,20 March 2017 to 19 September 2022										
Urgency status	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023*	Total			
Elective Super-urgent	1035 (89) 134 (11)	1075 (88) 140 (12)	1065 (89) 132 (11)	909 (90) 104 (10)	1114 (91) 109 (9)	549 (86) 86 (14)	5747 (89) 705 (11)			
Total	1169 (100)	1215 (100)	1197 (100)	1013 (100)	1223 (100)	635 (100)	6452 (100)			
*20 March 2022 -	19 September	2022								

#### 3.2. REGISTRATION ACTIVITY - SUPER-URGENT

3.2.1. Table 2 compares the twelve months pre the introduction of NLOS and the fifty-four months post the introduction of NLOS by super-urgent category. The proportion of patients registered as either category 8 (HAT on days 0 to 21) or 9 (Early graft dysfunction on days 0 to 7) was 26% in the year prior and ranged between 18% and 28% in the years post NLOS. Appendix A shows the descriptions of each of the categories.

Super-urgent category	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023*	Total
<u><u></u></u>							
1	2 (1)	3 (2)	4 (3)	3 (3)	5 (5)	1 (1)	18 (3)
2	11 (8)	10 (7)	11 (8)	5 (5)	5 (5)	6 (7)	48 (7)
3	4 (3)	9 (6)	6 (5)	9 (9)	7 (6)	6 (7)	41 (6)
4	2 (1)	2 (1)	2 (2)	3 (3)	4 (4)	0 (0)	13 (2)
5	11 (8)	5 (4)	3 (2)	4 (4)	8 (7)	9 (10)	40 (6)
6	54 (40)	56 (40)	50 (38)	41 (39)	40 (37)	37 (43)	278 (39)
7	6 (4)	3 (2)	9 (7)	8 (8)	10 (9)	4 (5)	40 (6)
8	22 (16)	19 (14)	14 (11)	9 (9)	8 (7)	11 (13)	83 (12)
9	13 (10)	20 (14)	15 (11)	11 (11)	12 (11)	6 (7)	77 (11)
10	4 (3)	4 (3)	6 (5)	0 (0)	0 (0)	1 (1)	15 (2)
20	3 (2)	5 (4)	7 (5)	6 (6)	5 (5)	5 (6)	31 (4)
88	2 (1)	4 (3)	5 (4)	5 (5)	5 (5)	0 (0)	21 (3)
Total	134 (100)	140 (100)	132 (100)	104 (100)	109 (100)	86 (100)	705 (100)

#### 3.3. REGISTRATION ACTIVITY - ELECTIVE

3.3.1. Table 3 compares the twelve months pre the introduction of NLOS and the fifty-four months post the introduction of NLOS for NHS Group 1 elective registrations by age and type of patient. There was no statistically significant associations between patient age group and time periods (Chisquared p-value =0.63).

Table 3				Type of elective patient by time period for elective registrations in the UK, 20 March 2017 to 19 September 2022											
Type of patient Overall	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023*	Total								
Adult elective <sup>1</sup> CLD HCC/ HCC downstaging Variant syndrome ACLF Liver/ cardiothoracic	<b>951 (92)</b> 674 (71) 193 (20) 83 (9) 0 (0) 1 (0)	<b>990 (92)</b> 721 (73) 195 (20) 71 (7) 1 (0) 2 (0)	<b>980 (92)</b> 739 (75) 178 (18) 56 (6) 2 (0) 5 (1)	<b>826 (91)</b> 637 (77) 147 (18) 38 (5) 2 (0) 2 (0)	<b>1037 (93)</b> 788 (76) 167 (16) 63 (6) 13 (1) 6 (1)	<b>504 (92)</b> 376 (75) 85 (17) 35 (7) 7 (1) 1 (0)	<b>5288 (92)</b> 3935 (74) 965 (18) 346 (7) 25 (0) 17 (0)								
Paediatric elective <sup>2</sup> Hepatoblastoma/ Prioritised Paediatric Non hepatoblastoma Liver/ cardiothoracic	<b>84 (8)</b> 3 (4) 81 (96) 0 (0)	<b>85 (8)</b> 10 (12) 74 (87) 1 (1)	<b>85 (8)</b> 10 (12) 75 (88) 0 (0)	<b>83 (9)</b> 21 (25) 62 (75) 0 (0)	<b>77 (7)</b> 16 (21) 59 (77) 2 (3)	<b>45 (8)</b> 8 (18) 37 (82) 0 (0)	<b>459 (8)</b> 68 (15) 388 (85) 3 (1)								

#### \*20 March 2022 - 19 September 2022

<sup>1</sup> Includes 17 CLD, 1 HCC and 1 Variant syndrome patient aged 17 years or over and weighing 40kg or under (1 in the twelve months prior and 18 in the fifty-four months post); 13 were dual-listed as small adults (1 in the twelve months prior and 12 in the fifty-four months post)

<sup>2</sup> Includes 4 hepatoblastoma and 81 non hepatoblastoma patients aged less than 17 years and weighing 40kg or over (20 in the twelve months prior and 65 in the fifty-four months post); 63 were dual-listed as large paediatrics (5 in the fifty-four months prior and 58 in the fifty-four months post)

- 3.3.2. **Table 4** compares the twelve months pre and the fifty-four months post the introduction of NLOS for each type of adult patient registered over the last 66 months by transplant number. The majority of patients were registered for a first liver transplant and there were no statistically significant associations between whether patient was registered for a first transplant or not and the time period (Chi-squared p-value=0.46).
- 3.3.3. All but two of the HCC patients were registered for a first graft. Both patients registered for a second graft had a UKELD less than 49, encephalopathy grade 0 and no current ascites.

	nt number by 2017 to 19 Se			ive registration	ons in the UK	,	
	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023*	Total
CLD <sup>1</sup> (Chi-squared p-va	lue=0.32)						
1 <sup>st</sup> graft	597 (89)	652 (90)	656 (89)	570 (89)	723 (92)	335 (89)	3533 (90)
2 <sup>nd</sup> graft	64 (9)	57 (8)	70 (9)	57 (9)	48 (6)	32 (9)	328 (8)
3 <sup>rd</sup> graft	9 (1)	12 (2)	11 (1)	9 (1)	15 (2)	8 (2)	64 (2)
4 <sup>th</sup> graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	9 (0)
6 <sup>th</sup> graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
HCC/HCC downstaging	∣ <b>g²</b> (Chi-square	∣ d p-value>0.9	9)				
1 <sup>st</sup> graft	192 (99)	194 (99)	178 (100)	147 (100)	167 (100)	85 (100)	963 (100)
2 <sup>nd</sup> graft	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (0)
Variant syndrome <sup>3</sup> (Ch	i-squared p-va	alue=0.14)					
1 <sup>st</sup> graft	73 (88)	61 (86)	55 (98)	35 (92)	59 (94)	33 (94)	316 (91)
2 <sup>nd</sup> graft	10 (12)	10 (14)	0 (0)	3 (8)	3 (5)	2 (6)	28 (8)
3 <sup>rd</sup> graft	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	2 (1)
Overall adult elective <sup>4</sup>	(Chi-squared p	-value=0.46)					
1 <sup>st</sup> graft	863 (91)	910 (92)	896 (91)	756 (92)	967 (93)	461 (91)	4853 (92)
2 <sup>nd</sup> graft	75 (8)	68 (7)	70 (7)	60 (7)	51 (5)	34 (7)	358 (7)
3 <sup>rd</sup> graft	9 (1)	12 (1)	12 (1)	9 (1)	17 (2)	8 (2)	67 (Ì)
4 <sup>th</sup> graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	9 (0)
6 <sup>th</sup> graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Total	951 (100)	990 (100)	980 (100)	826 (100)	1037 (100)	504 (100)	5288 (100)

\*20 March 2022 - 19 September 2022

<sup>1</sup> One patient dual-listed was registered for a second graft in the twelve months prior whilst six were registered for a first graft, one for a second graft, three for a third graft and one for a fourth graft in the fifty-four months post.

<sup>2</sup> Includes HCC downstaging all of whom were registered for first graft.

<sup>3</sup> One patient dual-listed was registered for a second graft in the fifty-four months post.

<sup>4</sup> Includes liver and cardiothoracic patients (all of whom were registered for first graft) and hepatoblastoma tier patients/ACLF/prioritised paediatric patient (all whom were registered for a first graft except for one registered for a third graft).

3.3.4. **Table 5** shows compares the median and interquartile age at registration for the twelve months pre and the fifty-four months post the introduction of NLOS for each type of adult patient registered over the last 66 months. There were no statistically significant differences in the median recipient age (Kruskal-Wallis p-value≥0.24).

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023*	Total
CLD <sup>1</sup> (Kruskal-Wallis p-v	•						
N	674	721	739	637	788	376	3935
Median (IQR)	53 (44 - 61)	54 (44 - 61)	54 (45 - 61)	54 (44 - 60)	53.5 (43 - 60)	54 (43 - 61)	54 (44 - 61)
Range	17 - 76	17 - 73	17 - 74	17 - 71	17 - 74	18 - 71	17 - 76
HCC/HCC downstaging	, Kruskal-Walli	s p-value=0.5	9)				
N	193	195	178	147	167	85	965
Median (IQR)	60 (55 - 65)	61 (56 - 65)	61 (55 - 66)	60 (56 - 64)	60 (56 - 66)	62 (58 - 65)	61 (56 - 65)
Range	20 - 75	21 - 73	21 - 72	19 - 73	43 - 73	43 - 72	19 - 75
Variant syndrome (Krus	kal-Wallis p-va	lue=0.76)					
N	83	71	56	38	63	35	346
Median (IQR)	49 (38 - 55)	51 (41 - 58)	48.5 (37.5 - 57.5)	48 (39 - 56)	48 (36 - 56)	52 (37 - 59)	48.5 (38 - 57)
Range	17 - 71	18 - 70	18 - 70	19 - 66	17 - 71	22 - 64	17 - 71
Overall adult elective <sup>2</sup> (	Kruskal-Wallis	p-value=0.24)	i )				
Ν	951	990	980	826	1037	504	5288
Median (IQR)	55 (46 - 62)	56 (47 - 62)	55 (47 - 62)	55 (45 - 61)	54 (45 - 61)	56.5 (45 - 62)	55 (46 - 62)
Range	17 - 76	17 - 73	17 - 74	17 - 73	17 - 74	18 - 72	17 - 76

\*20 March 2022 - 19 September 2022

<sup>1</sup> There was one patient dual-listed in the twelve months prior and 12 in the fifty-four months post

<sup>2</sup> Includes liver and cardiothoracic patients and hepatoblastoma tier/ACLF patients

#### 3.4. POST-REGISTRATION OUTCOME

- 3.4.1. **Table 6** shows the one and three-month registration outcome for adult elective NHS Group 1 liver patients registered during the fifty-one months since the implementation of the NLOS, 20 March 2018 -19 June 2022, along with the prior twelve-month period, 20 December 2016 19 December 2017. Note that the 2022/2023 period covers 3 months due to time to follow-up. There were 1,037 adult elective registrations in the 2021/2022 period post NLOS and 406 (39%) received a transplant within 3 months of registration. The corresponding three-month transplant rate for patients registered during the twelve months in 2016/2017 was 50%. There were statistically significant differences between the time periods and registration outcome at one month and three month (Chi-squared p-value<0.0001 for both).
- 3.4.2. Table 6 also shows the six-month registration outcome for adult elective patients registered during the forty-eight months since the implementation of the NLOS, 20 March 2018 -19 March 2022, along with the prior twelve-month period, 20 September 2016 19 September 2017. There were statistically significant differences between the time periods and registration outcome at six months (Chi-squared p-value<0.0001). 526 (51%) of the 1,037 registrations were transplanted within 6 months in 2021/2022 period compared with 62% in 2016/2017. The proportion of patients who either died on the list or were removed due to condition deterioration within six months was 6% in the 2021/2022 period post NLOS compared with 8% in the 2016/2017 period prior.</p>


Table 6Registration outcomeSeptember 2016 to 19		ve NHS Group	1 registrations	on the UK live	r transplant list	t, <b>20</b>
Registration outcome	2016/2017 <sup>1</sup>	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023 <sup>2</sup>
One-month outcome (Chi-square	ed p-value<0.00	001)				
Remained active/suspended	656 (69)	626 (63)	644 (66)	553 (67)	748 (72)	168 (68)
Died/ removed due to condition deterioration <sup>3</sup>	21 (2)	14 (1)	10 (1)	20 (2)	17 (2)	9 (4)
Removed due to other reasons	5 (1)	10 (1)	10 (1)	31 (3)	17 (2)	1 (0)
Transplanted	263 (28)	337 (34)	314 (32)	222 (27)	255 (25)	70 (28)
Total	945 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	248 (100)
Three-month outcome (Chi-squa	ared p-value<0.	0001)				
Remained active/suspended	409 (43)	419 (42)	455 (47)	415 (50)	575 (55)	136 (55)
Died/ removed due to condition deterioration <sup>3</sup>	55 (6)	32 (3)	27 (3)	39 (5)	35 (3)	13 (5)
Removed due to other reasons	13 (1)	18 (2)	18 (2)	39 (5)	21 (2)	2 (1)
Transplanted	468 (50)	518 (52)	478 (49)	333 (40)	406 (39)	97 (39)
Total	945 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	248 (100)
Six-month outcome (Chi-square						
Remained active/suspended	241 (27)	275 (28)	316 (32)	283 (34)	421 (41)	
Died/ removed due to condition deterioration <sup>3</sup>	68 (8)	44 (4)	48 (5)	72 (9)	62 (6)	
Removed due to other reasons	31 (3)	29 (3)	24 (2)	53 (6)	28 (3)	
Transplanted	566 (62)	639 (65)	590 (60)	418 (51)	526 (51)	
Total	906 (100)	987 (100)	978 (100)	826 (100)	1037 (100)	

<sup>1</sup>20 December 2016 to 19 December 2017 for one and three-month outcomes and 20 September 2016 to 19 September 2017 for six month outcome


<sup>2</sup>20 March 2022 to 19 June 2022 for one and three month outcome

<sup>3</sup> Includes patients removed as registered onto super-urgent list


- 3.4.3. **Figure 3** shows the three-month registration outcome by quarter and type of adult elective patient. HCC downstaging registrations are included with HCC registrations. The proportion of CLD patients registered post NLOS and transplanted in the first three months post-registration ranged between 41 and 63% compared with 46 and 55% of registrations in the year prior. There was a statistically significant association between three-month registration outcome and time period of registration for CLD patients and HCC/HCC downstaging patients (Chi-squared p-value<0.01) but not variant syndrome patients (Chi-squared p-value≥0.1).
- 3.4.4. Equivalent charts for six-month are presented in **Figure B1** in **Appendix B** and show consistent results with the three-month outcome chart for CLD and HCC/HCC downstaging patients. There was a statistically significant association between six-month registration outcome and time period of registration for variant syndrome patients (Chi-squared p-value<0.04).




3.4.5.**Figure 4** shows the three-month registration outcome by quarter and age group. There was a statistically significant association (Chi-squared p-value<0.02) between registration outcome and time period of registration for all age groups except for 17-29 years. Equivalent charts for six-month are presented in **Figure B2** in **Appendix B** and show consistent results with the three-month outcome chart for 17-25, 25-39, 50-59 and 60+ years.



3.4.6. Figure 5 shows the three-month registration outcome by quarter and whether the patient was registered for a first graft or regraft. The proportion of first graft patients registered post NLOS and transplanted in the first three months post-registration ranges between 36 and 60% compared with 46 and 53% of registrations in the year prior. The proportion of re-graft patients registered post NLOS and transplanted in the first three months post-registrations in the year prior. The proportion of re-graft patients registered post NLOS and transplanted in the first three months post-registration ranged between 14 and 50% compared with 25 and 53% of registrations in the year prior. There was a statistically significant association between registration outcome and time period of registration for patients registered for a first graft but not for regraft patients (Chi-squared p-value <0.01 and 0.43 respectively). Equivalent charts for six-month are presented in Figure B3 in Appendix B and show consistent results with the three-month outcome chart.</p>



3.4.7. **Figure 6** shows the three-month registration outcome by quarter. The mortality rate in the first three months ranged between 2% and 8% in the quarters since the introduction of NLOS compared with between 4% and 7% in the quarters prior. Equivalent charts for six-month are presented in **Figure B4** in **Appendix B** and show consistent results with the three-month outcome chart.



3.4.8. Fifty-two patients listed for a regraft, either on the list on 20 March 2018 or registered during the fifty-four months post NLOS, were removed from the transplant list (regardless of reason).
 Table 7 shows the other reasons for removal from the transplant list for each of the 52 patients.

Patient number	Centre	Month removed	Time from previous tx	Time on the list	Reason for removal	Other reasons given
1	6	March 2018	1940	2562	Condition deteriorated	Deterioration of Hocum therefore not fit for OLTX
2	6	April 2018	1245	2	Other	At patients request
3	5	May 2018	527	212	Condition deteriorated	
4	5	May 2018	1178	266	Condition improved	
5	6	July 2018	1106	247	Condition improved	
6	5	August 2018	480	596	Condition deteriorated	Awaiting cardiology review,
7	6	September 2018	1220	55	Condition deteriorated	episode of SVT yesterday Patient has developed lung
8	6	December 2018	2799	24	Condition deteriorated	cancer Has extra hepatic collections,
9	3	February 2019	1903	337	Condition deteriorated	needs addressing Further investigations required
10	4	March 2019	2220	392	Condition improved	for anaemia and cardiac function
11	5	April 2019	2736	6	Condition deteriorated	Patient has deteriorated and is no longer a transplant candidate.
12	6	June 2019	2564	74	Condition improved	no longer a transplant candidate.
12	3	September 2019	158	150	Condition deteriorated	HCC in nodes outsides liver
14	5	October 2019	3351	66	Condition deteriorated	Patient has developed multi-organ failure, rising lactate in the context of sepsis.
15	6	November 2019	5275	879	Condition deteriorated	Pt requires full assessment for retransplant now, after a long period of suspension on the waiting list since Aug 2018. Deemed medically too high risk to receive a transplant
16	3	December 2019	49	13	Condition improved	Clinically improving. No longer has ar indication for transplant
17	7	January 2020	179	117	Condition Deteriorated	HCC metastases
18	5	February 2020	7655	164	Condition Deteriorated	super urgent request sent through via National appeal.
19	5	February 2020	808	604	Condition deteriorated	Requires Haematology review and bone marrow biopsy due to neutropenia
20	4	February 2020	103	30	Condition improved	OPA 13.2.20
21	3	February 2020	645	93	Condition improved	
22	1	March 2020	6929	10	Condition deteriorated	
23	5	July 2020	2907	609	Condition deteriorated	
23 24	6	July 2020	5537	764	Other	Patient now for palliative care in their
25	3	September 2020	56	1	Condition improved	local hospital Not clinically urgent
26	5	March 2021	11009	927	Condition deteriorated	Awaiting Vascular review, lower limb numbness and pain, known SMV calcification
27	2	April 2021	62	15	Other	Moved to su waiting list
28	6	April 2021	710	3	Condition improved	Request made by Hepatologist to Suspend as improved
29	6	May 2021	5498	74	Condition deteriorated	-
30 31	7 4	May 2021 May 2021	10069 26	654 0	Condition deteriorated Registered onto the	Patient pyrexial; patient died
32	4	June 2021	545	381	super-urgent list Condition deteriorated	Admitted to ITU. Aim to get patient of ITU and to discharge with palliative
33	5	June 2021	6249	84	Condition improved	care Clinical condition improved since
34	6	August 2021	128	11	Condition deteriorated	listing Patient went for transplant found to have malignancy therefore

35	6	October 2021	198	739	Condition improved	
36	7	October 2021	168	103	Condition deteriorated	Patient too sick for liver transplant
37	2	October 2021	468	82	Patient/non-compliant	Following MDT - majority of the team do not support transplant due to concerns with compliance
38	5	October 2021	320	90	Condition deteriorated	
39	5	November 2021	1642	62	Condition deteriorated	Deteriorated and patient not keen on transplant
40	3	November 2021	1617	6	Condition deteriorated	
41	5	November 2021	1866	1256	Condition deteriorated	New PLTD diagnosis
42	2	November 2021	6605	42	Condition improved	Patient transferred and under assessment at new centre
43	6	December 2021	2649	457	Other	Drinking alcohol whilst on the waiting list
44	1	December 2021	53	4	Condition deteriorated	
45	6	January 2022	876	113	Condition improved	
46	6	March 2022	5352	32	Condition deteriorated	End of life care. Frailty. Refractory leg abscess. MOF.
47	2	April 2022	1463	185	Patient/non-compliant	
48	6	April 2022	1404	241	Condition improved	
49	4	May 2022	245	283	Condition improved	No indication for transplant-improved
50	5	June 2022	5910	698	Condition deteriorated	
51	3	July 2022	5802	65	Condition improved	
52	4	September 2022	513	448	Patient/non-compliant	Drinking alcohol whilst on the waiting list.

#### 3.5. LIVER OFFERING


- 3.5.1. Table 8 shows the overall UK deceased donor liver offering outcome between 20 March 2017 and 19 September 2022, by donor type and time period. 3975 DBD and 3896 DCD livers were offered for transplantation in the first fifty-four months of the scheme. Of the DBD livers offered, 3456 (87%) were retrieved for the purposes of transplantation and 2993 (87%) were transplanted (all but 26 were transplanted in the UK). The proportion of DBD livers offered and retrieved is very similar to the percentage for the 12 months prior to the introduction of the new scheme. Table 8 also shows the liver offering outcome for donors where at least one solid organ was retrieved for the purposes of transplantation.
- 3.5.2. **Table 9** shows, separately, the reasons for not offering, not retrieving and not transplanting livers by donor type and time period. The number in brackets are the corresponding values for solid organ donors where at least one organ was retrieved for the purposes of transplantation. Full breakdown of the reasons for non-retrieval and non-use are presented in **Appendix C**.


			DBI	)					C	DCD		
	17/18	18/19	19/20	20/21	21/22	22/23*	17/18	18/19	19/20	20/21	21/22	22/23*
1. ALL DONORS Number donors	1067	1074	1067	875	877	416	1164	1222	1275	717	1031	514
Liver not offered for donation Liver offered for donation	105 (10) 962 (90)	72 (7) 1002 (93)	69 (6) 998 (94)	84 (10) 791 (90)	80 (9) 797 (91)	29 (7) 387 (93)	212 (18) 952 (82)	225 (18) 997 (82)	237 (19) 1038 (81)	140 (20) 577 (80)	187 (18) 844 (82)	74 (14) 440 (86
Liver not retrieved (% offered) Liver retrieved (% offered)	118 (12) 844 (88)	143 (14) 859 (86)	• • •	117 (15) 674 (85)	. ,	37 (10) 350 (90)	652 (68) 300 (32)	741 (74) 256 (26)	751 (72) 287 (28)	407 (71) 170 (29)	533 (63) 311 (37)	251 (57 189 (43
Livers transplanted overseas (% retrieved) Livers transplanted in the UK (% retrieved) Liver not transplanted (% retrieved)	4 (0) 765 (91) 75 (9)	9 (1) 756 (88) 94 (11)	3 (0) 733 (85) 128 (15)	2 (0) 580 (86) 92 (14)	6 (1) 599 (84) 104 (15)	2 (1) 303 (87) 45 (13)	0 (0) 198 (66) 102 (34)	0 (0) 189 (74) 67 (26)	0 (0) 176 (61) 111 (39)	0 (0) 114 (67) 56 (33)	0 (0) 194 (62) 117 (38)	0 (0) 126 (67 63 (33)
Liver used for research (% not ransplanted)	44 (59)	52 (55)	68 (53)	5 (5)	10 (10)	2 (4)	63 (62)	39 (58)	62 (56)	5 (9)	8 (7)	4 (6)
2. SOLID ORGAN DONORS Number donors	949	967	962	752	784	393	616	641	655	388	621	314
Liver not offered for donation Liver offered for donation	45 (5) 904 (95)	28 (3) 939 (97)	23 (2) 939 (98)	23 (3) 729 (97)	27 (3) 757 (97)	15 (4) 378 (96)	44 (7) 572 (93)	51 (8) 590 (92)	41 (6) 614 (94)	31 (8) 357 (92)	51 (8) 570 (92)	16 (5) 298 (95
Liver not retrieved (% offered) Liver retrieved (% offered)	60 (7) 844 (93)	80 (9) 859 (91)	75 (8) 864 (92)	55 (8) 674 (92)	48 (6) 709 (94)	28 (7) 350 (93)	272 (48) 300 (52)	334 (57) 256 (43)	327 (53) 287 (47)	187 (52) 170 (48)	259 (45) 311 (55)	109 (37 189 (63
Livers transplanted overseas (% retrieved) Livers transplanted in the UK (% retrieved) Liver not transplanted (% retrieved)	4 (0) 765 (91) 75 (9)	9 (1) 756 (88) 94 (11)	3 (0) 733 (85) 128 (15)	2 (0) 580 (86) 92 (14)	6 (1) 599 (84) 104 (15)	2 (1) 303 (87) 45 (13)	0 (0) 198 (66) 102 (34)	0 (0) 189 (74) 67 (26)	0 (0) 176 (61) 111 (39)	0 (0) 114 (67) 56 (33)	0 (0) 194 (62) 117 (38)	0 (0) 126 (67 63 (33)
liver used for research (% not ransplanted)	44 (59)	52 (55)	68 (53)	5 (5)	10 (10)	2 (4)	63 (62)	39 (58)	62 (56)	5 (9)	8 (7)	4 (6)

			DBD	)					C	CD		
	17/18	18/19	19/20	20/21	21/22	22/23*	17/18	18/19	19/20	20/21	21/22	22/23
REASONS NOT OFFERED												
Family permission not sought	1 (1)	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	2 (2)	2 (2)	1 (1)	0 (0)	1 (.)	2 (1)
Family permission refused	20 (11)	10 (3)	8 (5)	3 (3)	7 (3)	2 (2)	26 (6)	18 (6)	3 (1)	9 (2)	9 (4)	4 (0)
Permission refused by coroner	18 (9)	7 (4)	0 (0)	5 (3)	7 (4)	5 (3)	5 (0)	9 (5)	10 (3)	4 (3)	8 (4)	1 (1)
Donor unsuitable - age	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8 (4)	5 (2)	10 (6)	26 (11)	7 (5)	0 (0)
Donor unsuitable - past history	30 (20)	17 (14)	21 (16)	19 (13)	18 (15)	9 (9)	51 (23)	54 (27)	48 (18)	27 (12)	52 (29)	17 (11
Donor unstable	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	4 (1)	1 (1)	2 (.) ´	0 (0)	0 (0)	0 (0)
Donor unsuitable - size	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)
Donor arrested	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)
Poor function	1 (0)	7 (6)	2 (2)	2 (2)	3 (2)	0 (0)	13 (5)	16 (7)	12 (6)	2 (1)	10 (6)	2 (2)
Infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (0)	1 (Ò)	0 (0)	0 (0)	0 (0)	1 (0)
Other disease	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Ischaemia time too long - warm	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Donor unsuitable - virology	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	8 (1)	2 (1)	3 (0)	7 (1)	2 (1)	1 (1)	26 (2)	18 (Ó)	26 (4)	7 (1)	12 (2)	3 (0)
Not reported	21 (1)	28 (0)	35 (0)	46 (0)	41 (0)	12 (0)	72 (1)	98 (0)	122 (0)	65 (1)	87 (0)	43 (0
Total not offered	105 (45)	72 (28)	69 (23)	84 (23)	80 (27)	29 (15)	212 (44)	225 (51)	237 (41)	140 (31)	187 (51)	74 (16
REASONS FOR NON-RETRIEVAL												
Donor unsuitable - medical	11 (0)	11 (2)	18 (4)	6 (2)	8 (4)	3 (3)	12 (1)	14 (3)	15 (4)	6 (1)	12 (7)	0 (0)
Donor unsuitable - non medical	3 (0)	11 (5)	3 (3)	2 (0)	3 (3)	2 (1)	19 (ÌŹ)	24 (ÌŚ)	27 (18)	13 (8)	16 (9)	11 (7
Donor age	5 (3)	5 (4)	2 (2)	1 (0)	2 (0)	0 (0)	142 (55)	198 (93)	181 (82́)	59 (28)	133 (65)	62 (3
Organ unsuitable - clinical	57 (32)	63 (37)	62 (40)	61 (39)	48 (29)	18 (13)	154 (86)	198 (107)	188 (96)	138 (82)	186 (109)	85 (4
Poor function	17 (11)	16 (12)́	16 (9) <sup>´</sup>	16 (8)	7 (6)	3 (2)	49 (32)	49 (32)	51 ( <u>3</u> 1)	30 (Ì7)	32 (24)	11 (6
Other	25 (14)́	37 (20)	33 (17)	31 (6)	20 (6)	11 (́9́)	276 (86)	258 (84́)	289 (9 <del>6</del> )	161 (51́)	154 (45)	82 (16
REASONS FOR NON-RETRIEVAL	118 (60)	143 (80)	134 (75)	117 (55)	88 (48)	37 (28)	652 (272́)	741 (334)	751 (327)	407 (187)	533 (259́)	251 (1

		DBD							DC	D		
	17/18	18/19	19/20	20/21	21/22	22/23*	17/18	18/19	19/20	20/21	21/22	22/23*
REASONS RETRIEVED BUT NOT TRANSPLANTED												
Donor unsuitable - medical	6 (6)	4 (4)	5 (5)	10 (10)	22 (22)	2 (2)	1 (1)	0 (0)	6 (6)	7 (7)	10 (10)	4 (4)
Donor unsuitable - non medical	1 (1)	0 (0)	1 (1)	1 (1)	8 (8)	0 (0)	0 (0)	1 (1)	1 (1)	3 (3)	5 (5)	2 (2)
Donor age	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	4 (4)
Organ unsuitable - clinical	12 (12)	19 (19)	25 (25)	46 (46)	40 (40)	24 (24)	17 (17)	17 (17)	19 (19)	16 (16)	45 (45)	25 (25)
Poor function	0 (0)	1 (1)	1 (1)	4 (4)	10 (10)	3 (3)	0 (0)	0 (0)	1 (1)	5 (5)	15 (15)	10 (10)
Other	56 (56)	70 (70)	96 (96)	31 (31)	24 (24)	16 (16)	84 (84)	49 (49)	84 (84)	25 (25)	40 (40)	18 (18)
TOTAL ORGANS RETRIEVED,	75 (75)	94 (94)	128 (128)	92 (92)	104 (104)	45 (45)	102 (102)	67 (67)	111 (111)	56 (56)	117 (117)	63 (63)
NOT TRANSPLANTED	. ,	· · ·	· · /	· · /	· · /	· · /	. ,	. ,	<b>、</b>	. ,	· · ·	. ,

- 3.5.3. **Figure 7** shows the DBD liver offering outcome for all livers offered regardless of whether any solid organs were retrieved for the purposes of transplantation. **Figure 7** shows that 277 livers were offered during the first quarter of NLOS which was the second highest number of livers offered during the 66 month period.
- 3.5.4. The percentage of organs retrieved and transplanted per quarter ranged from 77% to 82% in the year prior and 67% to 82% in the fifty-four months post the introduction of NLOS. The percentage of livers retrieved and used for research ranged between 3% and 6% in the year prior and 0% to 10% for the fifty-four months post the introduction of NLOS.
- 3.5.5. **Figure 8** shows the equivalent information for all solid organ donors where the liver was offered for transplantation and at least one organ (not necessarily the liver) was retrieved for the purposes of transplantation.





- 3.5.6. Figure 9a show the number of livers offered during the first fifty-four months of the new scheme at each stage of the liver offering pathway up to and including the liver and cardiothoracic section. Livers offered during COVID are included in Figure 9a but excluded at the elective stage of Figure 9b. 36 of the 3975 donors did not meet the DBD criteria at the start of the offering process and 31 were retrieved and transplanted. These livers are hence excluded from the offering pathway.
- 3.5.7. Livers from 457 donors meeting the DBD criteria were accepted and transplanted into super-urgent patients (including 20 super-urgent patients in Dublin). 519 livers were offered to hepatoblastoma/prioritised paediatric/ACLF patients and 59 were accepted and transplanted. 381 livers were offered to the liver and intestinal list and 38 were accepted and transplanted. Please note that a liver accepted and used at any stage may have been provisionally offered on to elective patients or fast-tracked before being accepted and used. These have not been included in the number of livers offered in later stages along with livers that may have been accepted, split and transplanted into two patients.
- 3.5.8. 853 livers were offered to liver and cardiothoracic patients and eight were accepted and transplanted combined liver and cardiothoracic patients. It should be noted that offers may be made when the cardiothoracic organs are unavailable.
- 3.5.9. Figure 9b shows the number of livers that were offered to elective patients and hadn't been accepted and used for super-urgent, hepatoblastoma, liver/intestinal and liver/cardiothoracic patients. Of the 3372 livers offered to elective patients, 3320 were adult donors and 52 were paediatric donors (aged less than 16 years or weighing 40 kg or less). 605 adult donors met the split criteria and 546 livers were offered to paediatric centres for paediatric/small adult patients. 151 of the 546 livers were accepted and transplanted. Thirty-one livers were only offered to paediatric patients and not offered to elective adult patient or fast-tracked.
- 3.5.10. 163 livers were offered to elective patients between 27 March and 9 July 2020.
- 3.5.11. Ninety percent of livers offered to elective patients were randomly allocated to the elective CLD/HCC pathway while ten percent were allocated to the variant syndrome pathway. Of the 2849 livers allocated to the CLD/HCC pathway, 2564 (90%) were offered to named patients and 1529 (60%) were accepted and transplanted. Of the 325 livers allocated to the VS pathway, 265 (82%) were offered and 124 (47%) were accepted and transplanted.





Figure 9A Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 September 2022





#### Figure 9B Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 September 2022

3.5.12. Table 10 shows the number of liver offers made to each UK liver transplant centre in either the twelve months prior to the new scheme or during the first fifty-four months of the new scheme. Livers offered to intestinal or liver/cardiothoracic patients have been excluded. The number of offers made to UK liver transplant centres has increased compared with the 12 months prior.

	2017/18		2018/19		2019/20		2020/21		2021/22		2022/23*	
	No. of offers (no. of donors)	Median (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) of offers per donor	No. of offers (no. of donors)	Median number (IQR) o offers per donor
A. All liver offer	rs											
Newcastle Leeds Cambridge Royal Free Kings College Birmingham Edinburgh	344 (323) 501 (435) 348 (323) 384 (352) 516 (455) 495 (417) 374 (351)	1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1)	431 (378) 645 (481) 479 (391) 567 (460) 1020 (640) 868 (583) 511 (426)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	432 (386) 733 (545) 455 (386) 489 (420) 901 (629) 829 (591) 470 (415)	$\begin{array}{c} 1 \ (1, \ 1) \\ 1 \ (1, \ 2) \\ 1 \ (1, \ 1) \\ 1 \ (1, \ 1) \\ 1 \ (1, \ 2) \\ 1 \ (1, \ 2) \\ 1 \ (1, \ 2) \\ 1 \ (1, \ 1) \end{array}$	402 (343) 632 (443) 434 (352) 463 (368) 808 (531) 673 (468) 509 (395)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	316 (286) 611 (445) 401 (348) 480 (376) 920 (565) 730 (488) 407 (346)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	151 (132) 277 (211) 195 (172) 178 (140) 398 (252) 352 (232) 190 (165)	1 (1, 1 1 (1, 1 1 (1, 1 1 (1, 1 1 (1, 2 1 (1, 2 1 (1, 1
Total	2962 (944)	2 (1, 5)	4521 (984)	3 (2, 7)	4309 (986)	3 (1, 7)	3921 (777)	4 (1, 8)	3865 (786)	4 (1, 8)	1741 (385)	3 (1, 7)
B. All liver offer	rs for livers u	ltimately tra	ansplanted									
Newcastle Leeds Cambridge Royal Free Kings College Birmingham Edinburgh	174 (161) 324 (277) 191 (173) 209 (193) 327 (287) 313 (261) 209 (192)	$\begin{array}{c}1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\\1 \ (1, \ 1)\end{array}$	211 (192) 367 (276) 263 (221) 321 (264) 656 (423) 540 (380) 273 (231)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	208 (184) 429 (320) 240 (203) 237 (199) 546 (397) 507 (368) 221 (192)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	205 (176) 376 (263) 231 (188) 250 (196) 511 (343) 409 (294) 283 (217)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	157 (139) 376 (273) 205 (182) 265 (208) 607 (386) 476 (318) 211 (177)	1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)	76 (68) 187 (144) 119 (104) 95 (74) 290 (182) 227 (158) 112 (96)	1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 1) 1 (1, 2) 1 (1, 2) 1 (1, 1)
Total	1747 (755)	1 (1, 3)	2631 (750)	2 (1, 5)	2388 (726)	2 (1, 5)	2265 (575)	3 (1, 6)	2297 (595)	3 (1, 6)	1106 (304)	3 (1, 5


3.5.13. Figure 10 shows, for livers that were ultimately transplanted, the outcome of liver offers made in either the last year prior to the new scheme or during the first fifty-four months of the new scheme. Fast-track offers that were not accepted and transplanted (i.e. declined or accepted and not used fast-track offers) as well as livers offered from either DCD or positive virology donors were excluded. It should be noted that offers of left and right lobes are included. The proportion of offers accepted and not used has increased compared with the 12 months prior. Figure 10A shows the equivalent for each transplant centre.








- 3.5.14. 6435 (35%) of the 18357 offers made in the first 54 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 4487 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.5.15. The number of named patient offers per donor ranged between 1 and 10 with a median of one named patient offers per donor. The number of named offers per patient ranged between 1 and 27 with a median of two offers per patient. Forty one patients at 7 centres were offered 11 or more livers in the fifty-four month time period (17 were offered 11 livers, 9 were offered 12 livers, 4 were offered 13 livers, 4 were offered 14 livers, 1 was offered 15 livers, 2 were offered 17, 1 was offered 21 and 3 were offered 27 livers).
- 3.5.16. **Table 11** shows the outcome of named patient liver offers made during the first fifty-four months of the new scheme by type of patient. It also shows the offer outcome after excluding named patients offers for livers that were ultimately not transplanted. Overall, forty-four percent of named patient offers were accepted and 26% were accepted and transplanted. The number of transplants will not agree with the flow chart in **Figure 9A** as **Table 11** includes all elective named patient offers and will include livers that were offered as a right lobe after being accepted for super-urgent and hepatoblastoma patients.
- 3.5.17. Figures 11A, 11B and 11C shows the outcome of named CLD patient liver offers made during the first fifty-four months of the new scheme for livers ultimately transplanted by aetiology, transplant centre and blood group respectively. There were statistically significant differences at a 5% significance level in the outcomes for patients with PSC (p=0.04) and AID (p=0.007). There were also statistically significant differences at a 5% significance level in the outcomes for patients at a 5% significance level in the outcomes for patients with PSC (p=0.04) and AID (p=0.007). There were also statistically significant differences at a 5% significance level in the outcomes 8) for patients at Cambridge (p=0.04) and Edinburgh (p=0.00
- 3.5.18. **Figures 12A** and **12B** for shows the outcome of named HCC patient liver offers made during the first fifty-four months of the new scheme for livers ultimately transplanted by transplant centre and blood group respectively. **Figures 13A** and **13B** show equivalent information for variant syndrome patients.


Type of patient	Disease group	Offer outcome for all named patient offers				Offer outcome for all named patient offers for livers that we ultimately transplanted				
		Declined	Accepted but not used	Transplanted	Total	Declined	Accepted but not used	Transplanted	Total	
Chronic Liver	2018/2019	790 (55)	246 (17)	411 (28)	1447	492 (47)	142 (14)	411 (39)	1045	
Disease (CLD)	2019/2020	613 (50)	250 (20)	361 (29)	1224	346 (42)	118 (14)	361 (44)	825	
	2020/2021 <sup>1</sup>	544 (59)	162 (17)	223 (24)	929	315 (51)	78 (13)	223 (36)	616	
	2021/2022	796 (58)	252 (18)	336 (24)	1384	493 (51)	131 (14)	336 (35)	960	
	2022/2023 <sup>2</sup>	261 (51)	99 (19)	153 (30)	513	174 (46)	48 (13)	153 (41)	375	
	Total	3004 (55)	1009 (18)	1484 (27)	5497	1820 (48)	517 (14)	1484 (39)	3821	
нсс	2018/2019	31 (53)	12 (20)	16 (27)	59	24 (53)	5 (11)	16 (36)	45	
	2019/2020	29 (44)	12 (18)	25 (38)	66	11 (24)	9 (20)	25 (56)	45	
	2020/2021 <sup>1</sup>	31 (57)	13 (24)	10 (19)	54	25 (61)	6 (15)	10 (24)	41	
	2021/2022	39 (58)	11 (16)	17 (25)	67	17 (44)	5 (13)	17 (44)	39	
	2022/2023 <sup>2</sup>	23 (56)	8 (20)	10 (24)	41	18 (56)	4 (13)	10 (31)	32	
	Total	153 (53)	56 (20)	78 (27)	287	95 (47)	29 (14)	78 (39)	202	
/ariant	2018/2019	80 (56)	27 (19)	35 (25)	142	55 (53)	14 (13)	35 (34)	104	
syndrome	2019/2020	92 (58)	28 (18)	39 (25)	159	66 (55)	16 (13)	39 (32)	121	
	2020/2021 <sup>1</sup>	58 (64)	19 (21)	13 (14)	90	22 (50)	9 (20)	13 (30)	44	
	2021/2022	132 (68)	38 (19)	25 (13)	195	94 (65)	26 (18)	25 (17)	145	
	2022/2023 <sup>2</sup>	40 (62)	12 (18)	13 (20)	65	30 (60)	7 (14)	13 (26)	50	
	Total	402 (62)	124 (19)	125 (19)	651	267 (58)	72 (16)	125 (27)	464	
otal named pa	atient offers	3559 (55)	1189 (18)	1687 (26)	6435	2182 (49)	618 (14)	1687 (38)	4487	

















36

3.5.19. **Table 12** shows the median Transplant Benefit Score (TBS) at time of offer for named elective CLD patient offers for *livers ultimately transplanted* by, separately, year group, aetiology, blood group and centre. Overall, the median TBS ranged between 1124 and 1233 days by year. **Table 13** shows equivalent information for HCC named patient offers.

Table 12										lisease	(CLD) patier	t offers for live	rs ultim	nately trans	splanted,
	20 Widi	2018/		mber	2022 (e) 2019	xcluding 27 M 9/20		2020 10 9 2020			2021/2	2		2022/2	3*
Disease group	Ν	Med	IQR	Ν	Med	IQR	Ν	Med	IQR	Ν	Median	IQR	Ν	Median	IQR
Hepatitis C	33	1057	920 - 1251	19	1170	926 - 1392	17	1107	994 - 1304	24	1239	1056 - 1376	12	1187	1096 - 1290
ALD	281	1247	1032 - 1347	264	1230	1080 - 1353	192	1185	976 - 1307	315	1212	1026 - 1348	99	1247	1133 - 1390
Hepatitis B	18	1062	971 - 1380	6	1182	998 - 1406	7	1370	1261 - 1555	14	971	833 - 1221	1	1165	1165 - 1165
PSC	105	1199	1017 - 1316	98	1179	1092 - 1281	83	1084	838 - 1221	126	1167	968 - 1258	49	1191	983 - 1300
PBC	86	1081	1007 - 1223	56	1089	1015 - 1212	74	1091	949 - 1256	75	1037	870 - 1227	40	1236	1094 - 1270
AID	131	1259	1107 - 1379	69	1202	1005 - 1332	42	1284	1202 - 1354	80	1215	994 - 1432	29	1290	1234 - 1442
Metabolic	201	1220	1051 - 1326	176	1169	1041 - 1310	104	1157	1032 - 1265	190	1243	1082 - 1350	87	1264	1149 - 1349
Other	28	992	797 - 1080	26	996	939 - 1163	28	1042	678 - 1168	36	1062	885 - 1246	21	1176	1149 - 1203
Retransplant	162	1117	1011 - 1236	111	1074	984 - 1199	69	1011	878 - 1122	100	1103	921 - 1238	37	1154	1090 - 1213
Centre	Ι														
Newcastle	82	1255	1085 - 1340	65	1128	1064 - 1280	51	1068	952 - 1264	65	1259	1184 - 1352	18	1187	939 - 1282
Leeds	103	1097	923 - 1289	99	1183	1031 - 1309	94	1094	932 - 1235	129	1186	1064 - 1288	55	1264	1158 - 1377
Cambridge	106	1205	997 - 1306	112	1223	1084 - 1310	77	1122	994 - 1224	122	1158	978 - 1313	51	1269	1196 - 1361
Royal Free	167	1190	996 - 1342	109	1154	1037 - 1255	92	1102	930 - 1276	121	1176	1027 - 1308	45	1182	1150 - 1305
Kings College	242	1168	1022 - 1310	192	1147	1006 - 1336	116	1165	1011 - 1254	208	1153	965 - 1266	71	1209	1090 - 1290
Birmingham	225	1201	1058 - 1317	172	1153	1016 - 1297	85	1162	917 - 1350	202	1127	958 - 1300	72	1172	1043 - 1313
Edinburgh	120	1132	1008 - 1283	76	1175	1041 - 1315	101	1147	1032 - 1270	113	1258	1120 - 1345	63	1252	1156 - 1338
Blood group															
0	460	1189	1057 - 1329	360	1234	1113 - 1346	246	1210	1071 - 1306	379	1253	1152 - 1346	155	1273	1218 - 1357
А	431	1190	997 - 1314	343	1082	976 - 1233	269	1063	905 - 1211	438	1081	919 - 1259	166	1166	1051 - 1282
В	88	1140	963 - 1291	71	1193	1061 - 1285	74	1107	972 - 1344	106	1190	971 - 1293	36	1169	1013 - 1294
AB	66	979	640 - 1273	51	1046	876 - 1363	27	1045	765 - 1126	37	813	460 - 1137	18	1188	906 - 1284
Overall	1045	1179	1017 - 1314	825	1169	1031 - 1303	616	1124	965 - 1274	960	1179	988 - 1304	375	1233	1124 - 1328

Table 13						re (TBS) for n xcluding 27 M				named	patient offers	for livers ultin	nately t	ransplante	d,
		2018/			2019	-		202			2021/2	2		2022/2	3*
	N	Med	IQR	Ν	Med	IQR	Ν	Med	IQR	Ν	Median	IQR	Ν	Median	IQR
Centre	I														
Newcastle	0	-	-	2	1161	1034 - 1289	5	-14	-55 - 570	4	564	254 - 697	0	-	-
Leeds	1	668	668 - 668	16	971	901 - 1090	10	516	-2 - 854	6	993	968 - 1036	16	1258	1124 - 1439
Cambridge	10	1322	1265 - 1458	2	867	297 - 1437	6	292	137 - 705	4	1196	553 - 1254	3	1518	1212 - 1530
Royal Free	9	1313	676 - 1409	7	507	242 - 943	0	-	-	3	1116	643 - 1152	0	-	-
Kings College	7	598	515 - 1104	8	1060	1051 - 1105	7	463	415 - 1318	13	1075	910 - 1371	3	1190	1000 - 1339
Birmingham	9	1026	642 - 1179	6	923	549 - 1062	5	1090	1051 - 1103	5	448	-103 - 582	3	1203	766 - 1365
Edinburgh	9	1081	1052 - 1120	4	784	470 - 1020	8	339	236 - 831	4	651	331 - 1063	7	1405	1359 - 1424
Blood group															
0	19	1285	1105 - 1381	13	1062	474 - 1164	8	914	704 - 1305	6	1134	904 - 1187	17	1385	1339 - 1425
Α	17	1256	855 - 1329	21	1034	920 - 1164	23	402	130 - 915	28	953	646 - 1196	10	1124	1000 - 1170
В	4	672	629 - 698	4	958	851 - 990	5	355	192 - 1028	1	943	943 - 943	4	1485	1415 - 1524
AB	5	545	515 - 598	7	549	348 - 899	5	276	-55 - 415	4	373	144 - 515	1	232	232 - 232
UKELD group															
<49	1	591	591 - 591	9	297	182 - 507	15	137	-6 - 415	4	9	-57 - 163	1	232	232 - 232
49-53	8	607	497 - 695	9	916	810 - 980	12	730	232 - 1070	13	643	448 - 1036	1	766	766 - 766
≥ 54	36	1261	1059 - 1358	27	1054	943 - 1227	14	914	767 - 1289	22	1029	910 - 1254	30	1362	1159 - 1425
Overall	45	1106	676 - 1315	45	980	775 - 1089	41	463	192 - 973	39	938	543 - 1152	32	1353	1137 - 1425

## 3.6. TRANSPLANT ACTIVITY

3.6.1. **Table 14** shows the urgency status and age group of DBD and DCD liver transplants performed in the UK between 20 March 2017 and 19 September 2022. The proportion of super-urgent transplants performed prior to NLOS implementation was similar to the proportion performed in 2021/22 (11% vs 12% respectively). However it should be noted that the number of super-urgent transplants performed between March and September 2022 has increased both adult and paediatric patients. There was no evidence of a statistically significant difference for adult DBD liver and adult liver/kidney transplants (overall Chi-squared p-value=0.13) however there was a significant difference for paediatric transplants (overall Chi-squared p-value=0.02). Highlighted in red are the transplants that will be analysed further in the rest of the section.

Table 14 Urgency status 20 March 2017		for deceased do 2022, as at 30 S		ants performed in	n the UK,	
	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)
DBD liver		l		l	I	I
Adult elective liver and liver/kidney	640 (78.1)	624 (77.5)	608 (77.8)	477 (76.8)	481 (74.6)	227 (69.8)
Adult elective multivisceral	6 (0.7)	5 (0.6)	6 (0.8)	1 (0.2)	9 (1.4)	5 (1.5)
Adult elective liver/ cardiothoracic	2 (0.2)	0 (0)	2 (0.3)	3 (0.5)	3 (0.5)	0 (0)
Adult super-urgent liver and liver/kidney	94 (11.5)	100 (12.4)	83 (10.6)	61 (9.8)	75 (11.6)	50 (15.4)
Adult super-urgent multivisceral	1 (0.1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Paediatric elective liver and liver/kidney	57 (7.0)	56 (7.0)	64 (8.2)	63 (10.1)	53 (8.2)	24 (7.4)
Paediatric elective multivisceral	6 (0.7)	3 (0.4)	2 (0.3)	4 (0.6)	2 (0.3)	1 (0.3)
Paediatric super-urgent liver and liver/kidney	13 (1.6)	17 (2.1)	16 (2.0)	12 (1.9)	22 (3.4)	18 (5.5)
Total UK DBD transplants	819 (80.5)	805 (81.0)	781 (81.5)	621 (84.4)	645 (77.0)	325 (71.4)
DCD liver						I
Adult elective liver and liver/kidney	190 (96.0)	184 (97.4)	173 (97.7)	110 (95.7)	189 (97.9)	127(97.7)
Adult super-urgent liver and liver/kidney	1 (0.5)	1 (0.5)	3 (1.7)	2 (1.7)	2 (1.0)	0 (0)
Paediatric elective liver and liver/kidney	7 (3.5)	3 (1.6)	1 (0.6)	2 (1.7)	2 (1.0)	3 (2.3)
Paediatric super-urgent liver and liver/kidney	0 (0)	1 (0.5)	0 (0)	1 (0.9)	0 (0)	0 (0)
Total UK DCD transplants	198 (19.5)	189 (19.0)	177 (18.5)	115 (15.6)	193 (23.0)	130 (28.6)
Total UK transplants	1017 (100)	994 (100)	958 (100)	736 (100)	838 (100)	455 (100)

3.6.2. Figure 14 shows the number of transplants over the time periods of interest, by transplant centre and donor type.




Figure 14

- 3.6.3. One hundred and forty of the 3676 adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are included in the rest of the section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients. Sixteen NHS group 2 transplants (1 performed at London Bridge and 15 performed at King's College) and three intestinal liver only transplants performed at Cambridge between August 2017 and September 2018 have been excluded from the rest of this section.
- 3.6.4. Table 15 and Table 16 show the demographics of adult elective liver and liver/kidney DBD and DCD transplants performed in the UK during the time periods of interest.

Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors,20 March 2017 to 19 September 2022 as at 30 September 2022

	l	I	I			1
	<b>2017/18</b> N (%)	<b>2018/19</b> N (%)	<b>2019/20</b> N (%)	<b>2020/21</b> N (%)	<b>2021/22</b> N (%)	2022/23
Total	635	622	<b>607</b>	476	481	N (%) <b>227</b>
Offer type						
Named patient Fast-track		493 (79.3) 129 (20.7)	443 (73.0) 164 (27.0)	346 (72.7) 130 (27.3)	395 (82.1) 86 (17.9)	187 (82.4) 40 (17.6)
Rank on matching run Median (IQR) (Range)		2 (1 – 4) (1 - 187)	2 (1 – 4) (1 – 191)	2 (1 – 5) (1 – 204)	2 (1 – 4) (1 – 362)	2 (1 - 4) (1 - 415)
Transplant Benefit Score						
Median (IQR)		1132.82 (881 – 1301)	1096.12 (885 – 1289)	1090.12 (838 – 1281)	1155.10 (923 – 1314)	1212.62 (1056 – 1348)
(Range)		(-493 – 1617)	(-549 – 1616)	(-1535 - 1563)	(-289 – 1600)	(-215 – 1635)
Transplant Type Liver only	615 (96.9)	609 (97.9)	593 (97.7)	469 (98.5)	475 (98.8)	224 (98.7)
Liver & kidney	20 (3.1)	13 (2.1)	14 (2.3)	7 (1.5)	6 (1.2)	3 (1.3)
Type of Liver Transplant						
Whole liver Split liver	596 (93.9) 39 (6.1)	582 (93.6) 40 (6.4)	569 (93.7) 37 (6.1)	443 (93.1) 33 (6.9)	447 (92.9) 34 (7.1)	212 (93.4) 15 (6.6)
Reduced liver	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	0 (0)
Recipient Age Group	27 (4.3)	37 (5.9)	35 (5.8)	34 (7.1)	25 (5.2)	12 (5.3)
26-39 years	95 (15.0)	68 (10.9)	64 (10.5)	41 (8.6)	49 (10.2)	30 (13.2)
40-49 years 50-59 years	98 (15.4) 208 (32.8)	75 (12.1) 202 (32.5)	68 (11.2) 213 (35.1)	78 (16.4) 170 (35.7)	85 (17.7) 133 (27.7)	26 (11.5) 60 (26.4)
60-69 years	193 (30.4)	232 (37.3)	212 (34.9)	144 (30.3)	174 (36.2)	94 (41.2)
70+ years Recipient Sex	14 (2.2)	8 (1.3)	15 (2.5)	9 (1.9)	15 (3.1)	5 (2.2)
Male	396 (62.4)	396 (63.7)	369 (60.8)	298 (62.6)	318 (66.1)	136 (59.9)
Female	239 (37.6)	226 (36.3)	238 (39.2)	178 (37.4)	163 (33.9)	91 (40.1)
Type of Patient CLD	477 (75.1)	486 (78.1)	471 (77.6)	398 (83.6)	402 (83.6)	185 (81.5)
HCC	104 (16.4)	72 (11.6)	80 (13.2)	54 (11.3) <sup>´</sup>	38 (7.9)	18 (7.9)
VS HCC downstaging	49 (7.7) 5 (0.8)	59 (9.5) 5 (0.8)	51 (8.4) 5 (0.8)	21 (4.4) 3 (0.6)	28 (5.8) 3 (0.6)	15 (6.6) 0 (0)
ACLF	0`(0)´	0`(0)´	0`(0)´	0`(0)	10 (2.1́)	9 (4.Ó)
Robert's Disease Group	100 (17 2)	70 (10 E)	95 (14 0)	EZ (12.0)	49 (10 0)	27 (11 0)
HCC HCV	109 (17.2) 23 (3.6)	78 (12.5) 12 (1.9)	85 (14.0) 16 (2.6)	57 (12.0) 9 (1.9)	48 (10.0) 6 (1.2)	27 (11.9) 2 (0.9)
ALD HBV	139 (21.9)	169 (27.2)	153 (25.2)	127 (26.7)	150 (31.2)	62 (27.3)
PSC	8 (1.3) 86 (13.5)	13 (2.1) 72 (11.6)	6 (1.0) 63 (10.4)	2 (0.4) 47 (9.9)	10 (2.1) 55 (11.4)	2 (0.9) 28 (12.3)
PBC AID	37 (5.8)	49 (7.9)	47 (7.7)	43 (9.0)	36 (7.5)	16 (7.0)
NAFLD	44 (6.9) 67 (10.6)	51 (8.2) 72 (11.6)	48 (7.9) 71 (11.7)	38 (8.0) 54 (11.3)	37 (7.7) 69 (14.3)	16 (7.0) 39 (17.2)
Metabolic (excl. NAFLD) Other	8 (1.3) 58 (9.1)	13 (2.1) 40 (6.4)	23 (3.8) 44 (7.2)	7 (1.5) 38 (8.0)	9 (1.9) 34 (7.1)	5 (2.2) 15 (6.6)
Retransplant	56 (8.8)	40 (8.4) 53 (8.5)	51 (8.4)	54 (11.3)	27 (5.6)	15 (6.6)

Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors,20 March 2017 to 19 September 2022 as at 30 September 2022

Total	2017/18 N (%) 635	2018/19 N (%) 622	2019/20 N (%) 607	2020/21 N (%) 476	2021/22 N (%) 481	2022/23 N (%) 227
Liver Transplant Number First liver transplant Second Third Fourth Sixth	579 (91.2) 46 (7.2) 7 (1.1) 2 (0.3) 1 (0.2)	568 (91.3) 51 (8.2) 3 (0.5) 0 (0) 0 (0)	556 (91.6) 40 (6.6) 8 (1.3) 3 (0.5) 0 (0)	421 (88.4) 45 (9.5) 9 (1.9) 1 (0.2) 0 (0)	454 (94.4) 18 (3.7) 8 (1.7) 1 (0.2) 0 (0)	212 (93.4) 14 (6.2) 1 (0.4) 0 (0) 0 (0)
Blood Group Compatibility* Identical Compatible Incompatible	628 (98.9) 6 (0.9) 1 (0.2)	608 (97.7) 14 (2.3) 0 (0)	574 (94.6) 33 (5.4) 0 (0)	451 (94.7) 25 (5.3) 0 (0)	460 (95.8) 20 (4.2) 0 (0)	214 (94.3) 13 (5.7) 0 (0)
<b>Zonal Transplants</b> Non zonal Zonal	167 (26.3) 468 (73.7)	488 (78.5) 134 (21.5)	486 (80.1) 121 (19.9)	398 (83.6) 78 (16.4)	389 (80.9) 92 (19.1)	180 (79.3) 47 (20.7)
Blood group matching* (D=donor, R=recipient) DO, RO DO, RA DO, RB DA, RO DA, RA DA, RAB DB, RB DB, RB DB, RAB AB, RAB	297 (46.8) 1 (0.2) 1 (0.2) 245 (38.6) 4 (0.6) 70 (11.0) 0 (0) 16 (2.5) vith unknown d	294 (47.3) 0 (0) 1 (0.2) 0 (0) 236 (37.9) 11 (1.8) 55 (8.8) 2 (0.3) 23 (3.7) onor blood gro	262 (43.2) 3 (0.5) 5 (0.8) 0 (0) 235 (38.7) 20 (3.3) 59 (9.7) 5 (0.8) 18 (3.0) oup in 2021/22	182 (38.2)  5 (1.1)  5 (1.1)  0 (0)  203 (42.6)  10 (2.1)  55 (11.6)  5 (1.1)  11 (2.3)	$\begin{array}{c} 171 \ (35.6) \\ 8 \ (1.7) \\ 5 \ (1.0) \\ 0 \ (0) \\ 213 \ (44.4) \\ 6 \ (1.3) \\ 52 \ (10.8) \\ 1 \ (0.2) \\ 24 \ (5.0) \end{array}$	81 (35.7) 3 (1.3) 4 (1.8) 0 (0) 105 (46.3) 5 (2.2) 21 (9.3) 1 (0.4) 7 (3.1)

# Table 16 Adult elective liver and liver/kidney transplants performed in the UK using livers from DCD<br/>donors, 20 March 2017 to 19 September 2022 as at 30 September 2022

						1
	<b>2017/18</b> N (%)	<b>2018/19</b> N (%)	<b>2019/20</b> N (%)	<b>2020/21</b> N (%)	<b>2021/22</b> N (%)	<b>2022/23</b> N (%)
Total	186	181	170	110	189	127
<b>Transplant Type</b> Liver only Liver & kidney	186 (100) 0 (0)	181 (100) 0 (0)	169 (99.4) 1 (0.6)	110 (100) 0 (0)	189 (100) 0 (0)	127 (100) 0 (0)
<b>Type of Liver Transplant</b> Whole liver	ed 186 (100)	181 (100)	170 (100)	110 (100)	189 (100)	127 (100)
Recipient Age Group 17-25 years 26-39 years 40-49 years 50-59 years 60-69 years 70+ years	4 (2.2) 10 (5.4) 24 (12.9) 76 (40.9) 66 (35.5) 6 (3.2)	5 (2.8) 17 (9.4) 23 (12.7) 73 (40.3) 57 (31.5) 6 (3.3)	5 (2.9) 16 (9.4) 25 (14.7) 55 (32.4) 68 (40.0) 1 (0.6)	1 (0.9) 14 (12.7) 17 (15.5) 36 (32.7) 39 (35.5) 3 (2.7)	1 (0.5) 19 (10.1) 35 (18.5) 83 (43.9) 48 (25.4) 3 (1.6)	1 (0.8) 17 (13.4) 19 (15) 44 (34.6) 43 (33.9) 3 (2.4)
<b>Recipient Sex</b> Male Female	119 (64.0) 67 (36.0)	129 (71.3) 52 (28.7)	106 (62.4) 64 (37.6)	76 (69.1) 34 (30.9)	132 (69.8) 57 (30.2)	97 (76.4) 30 (23.6)
Type of Patient CLD HCC VS HCC downstaging ACLF	123 (66.1) 52 (28.0) 9 (4.8) 2 (1.1) 0 (0)	86 (47.5) 83 (45.9) 5 (2.8) 7 (3.9) 0 (0)	107 (62.9) 58 (34.1) 1 (0.6) 4 (2.4) 0 (0)	72 (65.5) 33 (30.0) 2 (1.8) 3 (2.7) 0 (0)	104 (55.0) 73 (38.6) 8 (4.2) 3 (1.6) 1 (0.5)	75 (59.1) 45 (35.4) 5 (3.9) 0 (0) 2 (1.6)
Robert's Disease Group HCC HCV ALD HBV PSC PBC AID NAFLD Metabolic (excluding NAFLD) Other Retransplant	55 (29.6) 4 (2.2) 43 (23.1) 3 (1.6) 19 (10.2) 24 (12.9) 10 (5.4) 21 (11.3) 4 (2.2) 0 (0) 3 (1.6)	91 (50.3) 3 (1.7) 35 (19.3) 1 (0.6) 12 (6.6) 7 (3.9) 7 (3.9) 12 (6.6) 2 (1.1) 6 (3.3) 5 (2.8)	62 (36.5) 3 (1.8) 43 (25.3) 2 (1.2) 17 (10) 18 (10.6) 5 (2.9) 8 (4.7) 1 (0.6) 8 (4.7) 3 (1.8)	36 (32.7) 2 (1.8) 20 (18.2) 1 (0.9) 16 (14.5) 9 (8.2) 4 (3.6) 8 (7.3) 3 (2.7) 4 (3.6) 7 (6.4)	76 (40.2) 6 (3.2) 39 (20.6) 3 (1.6) 15 (7.9) 10 (5.3) 11 (5.8) 11 (5.8) 1 (0.5) 11 (5.8) 6 (3.2)	49 (38.6)2 (1.6)28 (22.0)4 (3.1)19 (15.0)5 (3.9)6 (4.7)9 (7.1)0 (0)3 (2.4)2 (1.6)
Liver Transplant Number First liver transplant Second Third	r 183 (98.4) 3 (1.6) 0 (0)	176 (97.2) 5 (2.8) 0 (0)	167 (98.2) 3 (1.8) 0 (0)	103 (93.6) 7 (6.4) 0 (0)	183 (96.8) 4 (2.1) 2 (1.1)	125 (98.4) 2 (1.6) 0 (0)
Blood Group Compatibil Identical Compatible Incompatible	ity* 185 (99.5) 1 (0.5) 0 (0)	174 (96.1) 7 (3.9) 0 (0)	161 (94.7) 9 (5.3) 0 (0)	109 (99.1) 1 (0.9) 0 (0)	182 (96.3) 7 (3.7) 0 (0)	123 (96.9) 4 (3.1) 0 (0)
<b>Zonal Transplants</b> Non zonal Zonal	65 (34.9) 121 (65.1)	74 (40.9) 107 (59.1)	65 (38.2) 105 (61.8)	42 (38.2) 68 (61.8)	77 (40.7) 112 (59.3)	47 (37.0) 80 (63.0)

donors, 20 March 2017 to 19 September 2022 as at 30 September 2022														
	<b>2017/18</b> N (%)	<b>2018/19</b> N (%)	<b>2019/20</b> N (%)	<b>2020/21</b> N (%)	<b>2021/22</b> N (%)	<b>2022/23</b> N (%)								
Total	186	181	170	110	189	127								
Blood group														
matching* (D=donor,														
R=recipient)														
DO, RO	95 (51.1)	79 (43.6)	68 (40.0)	52 (47.3)	88 (46.6)	60 (47.2)								
DO, RA	0 (0)	0 (0)	3 (1.8)	1 (0.9)	4 (2.1)	2 (1.6)								
DO, RB	0 (0)	5 (2.8)	5 (2.9)	0 (0)	2 (1.1)	2 (1.6)								
DA, RO	0 (0)	1 (0.6)	0 (0)	0 (0)	1 (0.5)	0 (0)								
DA, RA	70 (37.6)	74 (40.9)	77 (45.3)	48 (43.6)	73 (38.6)	52 (40.9)								
DA, RAB	1 (0.5)	1 (0.6)	0 (0)	0 (0)	0 (0)	0 (0)								
DB, RB	18 (9.7)	16 (8.8)	13 (7.6)	7 (6.4)	21 (11.1)	9 (7.1)								
DB, RAB	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	0 (0)								
DAB, RAB	2 (1.1)	5 (2.8)	3 (1.8)	2 (1.8)	0 (0)	2 (1.6)								

3.6.5. **Table 17** and **Table 18** shows the median waiting time to transplant for the adult elective transplants performed in the UK by transplant centre, blood group and type of patient, for DBD and DCD transplants respectfully. Overall, the median time to transplant was statistically significantly different across the time periods of interest for both DBD and DCD transplants (both with a Kruskal-Wallis p-value<0.0001).

Table 17					ansplant (d er 2022, as				er and live	er/kidr	ney transpl	ants perf	ormed	l in the UK	using live	rs fron	n DBD dono	rs,
	1	2017/18	2	1	2018/19		I	2019/20		1	2020/21		I	2021/2	, LAG(2	2)32	2022/23	
	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range
Overall	635	71 (23 - 198)	0 -1835	622	39 (9 - 138)	1 -1711	607	43 (10 - 144)	0 -1620	476	43 (9 - 164.5)	0 -1814	481	33 (9 - 105)	0 - 1470	227	34 (9 – 148)	1 - 2223
Type of patie	 nt			l						l								
CLD	477	65 (20 - 186)	0 -1519	486	29.5 (7 - 96)	1 -1518	471	25 (8 - 93)	0 - 1450	398	32 (8 - 150)	0 -1814	402	25 (8 - 84)	0 - 1470	185	23 (8 - 107)	1 - 2223
HCC	104	57 (23 - 184)	2 -1030	72	55 (22.5 - 145)	1 - 568	80	79 (33.5 - 167.5)	1 - 739	54	62 (24 - 128)	0 - 664	38	52 (21 - 107)	2 - 1400	18	64.5 (33 – 154)	4 – 769
VS	49	187 (79 - 543)	2 -1835	59	296 (100 - 836)	2 -1711	51	365 (174 - 613)	16 - 1620	21	367 (261 -585)	3 -1260	28	385 (200 - 612)	17 - 1326	15	464 (176 – 704)	52 – 2099
ACLF	0	-	-	0	-	-	0	-	-	0	-	-	10	11.5 (5 - 42)	2 - 968	9	10 (8 – 283)	3 - 1014
HCC downstaging	5	93 (63 - 131)	16 -384	5	14 (10 - 27)	6 - 65	5	58 (22 - 128)	17 - 204	3	44 (4 - 240)	4 - 240	3	42 (31 - 115)	31 - 115	0	-	-
Centre	ļ			I			-			ļ			-					
Newcastle	30	47 (17 - 111)	1 - 377	22	43 (17 - 96)	2 - 318	26	28.5 (14 - 85)	1 - 517	27	52 (20 - 190)	2 - 607	23	45 (13 - 110)	2 - 760	10	8 (4 – 12)	4 – 231
Leeds	108	64.5(26- 228.5)	1 -1402	66	41.5 (9 - 145)	1 -1341	79	33 (9 - 136)	1 - 1405	70	52.5 (14 - 159)	1 -1260	60	27.5 (9 - 113)	1 - 1187	33	19 (7 – 70)	1 – 769
Cambridge	71	74 (21 - 200)	0 -1343	65	36 (10 - 88)	1 - 760	60	17 (8.5 - 67)	1 - 656	35	23 (9 - 76)	0 - 679	50	37 (9 - 90)	0 - 633	16	13 (9 – 66.5)	2 – 169
Royal Free	84	99.5(29.5- 236.5)	0 - 945	83	33 (7 - 133)	1 -1261	91	37 (11 - 96)	1 - 971	57	39 (8 - 95)	0 - 699	65	28 (8 - 154)	2 - 592	33	50 (11 – 241)	3 – 704
Kings College	128	125 (45 - 374)	1 -1813	143	54 (11 - 252)	1 -1711	145	54 (11 - 164)	1 - 1620	115	32 (8 - 140)	0 -1687	117	33 (9 - 98)	1 - 968	51	85 (10 – 283)	2 – 2099
Birmingham	133	48 (15 - 137)	0 -1519	155	42 (11 - 105)	1 -1657	154	58.5 (9 - 204)	0 - 976	114	71.5 (8 - 262)	1 -1814	127	34 (9 - 146)	1 - 1470	60	64 (15 – 292.5)	1 – 2223
Edinburgh	81	42 (12 - 109)	0 -1835	88	24.5 (6 - 115.5)	1 -1124	52	46.5 (19 - 140)	2 - 640	58	45.5 (9 - 239)	1 - 749	39	17 (7 - 39)	1 - 452	24	15 (6.5 – 43.5)	2 - 198
Recipient blo	່ od groι			I			l			1			I					
0	298	113.5 (32-280)	0 -1835	294	60 (14 - 218)	1 -1711	262	56.5 (12 - 188)	1 - 1620	182	52.5 (11 - 216)	0 -1814	171	37 (10 - 132)	0 - 1470	81	57 (10 – 157)	1 – 1334
A	246	40 (16 - 93)	0 -1109	236	23 (6.5 - 76.5)	1 -1056	238	33 (9 - 100)	0 - 758	208	27 (7 - 138)	0 - 786	221	27 (8 - 100)	1 - 918	108	28 (8 – 148)	1 – 2223


# LAG(22)32


В	71	168 (49 -	0 -1813	56	57 (15 -	2 -1518	64	66 (18.5 -	2 - 865	60	66(21.5-	2 -1335	57	33 (9 -	2 - 592	25	50 (26 –	2 –
		384)			132)			167.5)			279.5)			103)			316)	2099
AB	20	25.5 (7.5	0 - 148	36	39.5 (13 -	1 - 466	43	19 (4 -	1 - 201	26	34 (15 -	5 - 340	32	24 (8 -	2 - 388	13	11 (5 – 20)	1 - 63
		- 66)			93)			43)			83)			57)			. ,	
		,			,			,			,			,				


Table 18					ansplant (d er 2022, as				er and live	er/kidı	ney transpl	ants perf	ormed	d in the UK	using liv	ers fr	om DCD do	onors,
	1	2017/18	2	I	2018/19		1	2019/20			2020/21		I	2021/22	LAG(22)	32	2022/23	2
	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	N	Median (IQR)	Range	Ν	Median (IQR)	Range
Overall	186	41.5 (14 - 142)	0 - 875	181	53 (20 - 128)	0 - 607	170	52 (19 - 142)	2 - 693	110	90.5 (29 - 205)	2 - 1278	189	98 (38 - 163)	1 - 923	127	137 (50 – 332)	1 – 911
Type of patient	I			I			I						I					
CLD	123	41 (13 - 143)	0 - 875	86	56 (20 - 125)	0 - 561	107	50 (15 - 147)	2 - 693	72	104.5(35. 5-205.5)	2 - 1101	104	102 (29.5- 178)	1 - 923	75	144 (39 – 344)	1 – 911
HCC	52	39.5 (16.5 - 110)	1 - 691	83	49 (20 - 148)	2 - 607	58	66.5 (35 - 135)	4 - 322	33	73 (29 - 144)	5 - 1278	73	95 (45 - 157)	2 - 822	45	128 (53 – 264)	2 - 542
VS	9	222 (32 - 347)	7 - 870	5	98 (72 - 300)	5 - 306	1	559	599	2	218 (215 - 221)	215 - 221	8	154 (103.5 -254.5)	70 -396	5	185 (137 – 243)	51 – 412
ACLF	0	-	-	0	-	-	0	-	-	0	-	-	1	2	2	0	-	-
HCC downstaging	2	53 (51 - 55)	51-55	7	47 (17 - 84)	11 -323	4	21 (12 - 35.5)	12 - 41	3	72 (27 - 216)	27 - 216	3	52 (24 - 143)	24 -143	2	102.5 (94 – 111)	94 - 111
Centre	Į						I						I					
Newcastle	5	106 (85 - 304)	5 - 304	3	304 (22- 452)	22 -452	4	144.5 (119 -371)	103 -588	2	110 (4 - 216)	4 - 216	13	152 (117 - 394)	5 - 817	5	195 (128 – 247)	26 – 258
Leeds	26	77.5 (13 - 297)	0 - 875	21	36 (12́ - 99)	2 - 517	21	36 (12 - 73)	2 - 565	15	56 (26 - 133)	5 - 511	16	115.5 (52 - 147)	4 - 923	12	58 (34 <sup>°</sup> – 399)	13 – 457
Cambridge	32	60 (28.5 - 151.5)	0 - 870	40	57.5(21.5- 128)	2 - 355	33	35 (14 - 78)	2 - 479	35	89 (46 - 211)	5 - 625	48	63 (21.5 - 142.5)	1 - 822	31	105 (24 – 258)	2 – 832
Royal Free	13	62 (24 - 234)	3 - 369	28	56.5(29.5- 144)	2 - 323	37	55 (23 - 135)	4 - 693	11	57 (23 - 205)	11 - 227	23	94 (27 - 148)	8 - 327	11	147 (92 – 388)	35 – 911
Kings College	46	67 (27 - 205)	4 - 691	38	72.5(34- 180)	4 - 607	37	84 (38 - 198)	3 - 559	31	123 (54 - 189)	8 - 1101	46	133.5 (52 - 162)	1 - 342	27	208 (81 – 359)	1 – 716
Birmingham	52	22.5 (13 - 42.5)	0 - 511	38	35.5 (16 - 80)	0 - 487	33	50 (30 - 125)	2 - 267	11	115 (7 - 221)	2 - 259	25	94 (60 - 218)	12 -418	28	96 (46 – 285)	4 – 763
Edinburgh	12	41.5 (10 - 94.5)	0 - 783	13	71 (38 - 333)	6 - 383	5	51 (44 - 151)	40 -224	5	42 (30 - 777)	27 - 1278	18	52.5 (16 - 151)	2 - 738	13	278 (97 – 496)	7 - 813
Recipient blood gr	oup			l			I						I					
0	95	62 (16 - 245)	0 - 875	79	69 (28 - 175)	0 - 561	68	69 (19 - 163.5)	2 - 693	52	115.5 (28 - 222)	7 - 1278	88	117 (45.5- 182.5)	1 - 822	60	153.5 (65.5 – 376)	2 – 832
А	70	29 (10 - 65)	0 - 351	74	37.5 (17 - 78)	2 - 457	80	50 (19 - 100.5)	2 - 588	49	78 (26 - 189)	2 - 530	77	93 (28 - 143)	2 - 476	54	116.5 (42 – 250)	2 – 911
В	18	55 (19 - 262)	4 - 783	21	103 (30- 171)	4 - 607	18	87 (43 - 183)	2 - 479	7	92 (57 - 119)	29 - 446	23	86 (40 - 271)	1 - 923	11	147 (64 – 412)	4 – 626
АВ	3	27 (9 - 111)	9 - 111	7	23 (9 - 94)	6 - 111	4	7.5 (6.5 - 22)	6 - 36	2	60.5 (48 - 73)	48 - 73	1	77	77	2	30.5 (1 – 60)	1 - 60


LAG(22)32

- 3.6.6. Figure 15 show the overall cold ischaemia time for the time periods of interest for DBD transplants while Figure 16 shows the cold ischaemia time for each centre. Figures 17 and Figure 18 show the equivalent information for DCD donor transplants.
- 3.6.7. There were statistically significant differences in the cold ischaemia time for adult elective DBD and DCD transplants over the time periods of interest (p=0.002 for DBD and p=0.007 for DCD). However, it should be noted that these results will change as NHSBT has not received all the first week transplant record forms which collect the cold ischaemia time. It should also be noted that this analysis does not adjust for whether machine perfusion was used.










### 3.7. NINETY-DAY POST-TRANSPLANT SURVIVAL


- 3.7.1.Figure 19 shows the unadjusted ninety-day patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first fifty-one months of NLOS. Table 18 and Table 19 shows the survival estimates and confidence intervals by blood group and type of patient for DBD and DCD transplants respectfully. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.
- 3.7.2.For DBD transplants, there was no overall statistically significant difference between the time periods of interest in ninety-day patient survival (log-rank p-value=0.15). There was a statistically significant difference in ninety-day survival for HCC patients (log-rank p-value=0.05) and CLD patients (log-rank p-value=0.03). There were no statistically significant differences between the time periods for the individual centres and blood groups (log-rank p-value≥0.23), apart from blood group B patients which had borderline significance (p=0.06).
- 3.7.3.For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in ninety-day patient survival (log-rank p-value=0.11). There was a borderline statistically significant difference in ninety-day survival for HCC patients (log-rank p-value=0.09) and CLD patients had no statistical significance (log-rank p-value=0.54). There were no statistically significant differences between the time periods for blood groups (log rank p-value≥0.41) and for the individual centres (log rank p-value≥0.29).



			1		1		i		1		i		
	No at risk	2017/18 % (95% CI)	No at risk	2018/19 % (95% CI)	No at risk	2019/20 % (95% CI)	No at risk	2020/21 % (95% CI)	No at risk	2021/22 % (95% CI)	No at risk	2022/2 % (95% CI)	23   Log-rank   p-value
Overall	579	96.2 (94.3, 97.5)	567	96.5 (94.6, 97.7)	555	98.2 (96.7, 99.0)	413	97.1 (94.9, 98.3)	440	97.9 (96, 98.9)	76	100 (-)	0.15
Type of patien			I				I				I		I
CLD	425	95.5 (93.1, 97.1)	436	95.9 (93.5, 97.4)	423	98.1 (96.3, 99.0)	340	98.2 (96.1, 99.2)	366	98.1 (96.0, 99.1)	66	100 (-)	0.03
HCC	104	98.1 (92.5, 99.5)	71	97.2 (89.2, 99.3)	80	98.8 (91.5, 99.8)	52	90.4 (78.4, 95.9)	36	100 (-)	5	100 (-)	0.05
VS	45	97.8 (85.3, 99.7)	55	100 (-)	47	97.9 (85.8, 99.7)	18	94.4 (66.6, 99.2)	26	95.0 (69.5, 99.3)	3	100 (-)	0.73
HCC	5	-	5	-	5	-	3	-	1	-	0	-	-
downstaging													
ACLF	0	100 (-)	0	100 (-)	0	100 (-)	0	100 (-)	10	90.0 (47.3, 98.5)	2	100 (-)	0.65
Recipient blo	od grou	ıp									1		
0	272	95.2 (91.9, 97.2)	265	97.4 (94.5, 98.7)	241	98.8 (96.2, 99.6)	159	97.4 (93.3, 99.0)	158	97.4 (93.1, 99.0)	26	100 (-)	0.23
A	224	96.4 (93.0, 98.2)	215	96.3 (92.7, 98.1)	216	97.7 (94.5, 99.0)	182	96.2 (92.1, 98.1)	196	98.5 (95.3, 99.5)	37	100 (-)	0.55
В	66	100 (-)	53	92.5 (81.1, 97.1)	59	98.3 (88.6, 99.8)	49	98.0 (86.4, 99.7)	54	100 (-)	9	100 (-)	0.06
AB	17	94.1 (65.0, 99.1)	34	97.1 (80.9, 99.6)	39	97.4 (83.2, 99.6)	23	100 (-)	32	93.8 (77.3, 98.4)	4	100 (-)	0.82
Centre			I				I				I		I
Newcastle	26	92.3 (72.6, 98.0)	22	95.5 (71.9, 99.3)	24	95.8 (73.9, 99.4)	24	100 (-)	22	100 (-)	0	100 (-)	0.53
Leeds	101	93.1 (86.0, 96.6)	59	91.5 (80.8, 96.4)	72	98.6 (90.5, 99.8)	56	94.6 (84.2, 98.2)	55	94.4 (83.6, 98.2)	19	100 (-)	0.42
Cambridge	67	97.0 (88.6, 99.2)	61	100 (-)	58	94.8 (84.8, 98.3)	28	100 (-)	49	100 (-)	4	100 (-)	0.25
Royal Free	82	96.3 (89.1, 98.8)	80	93.8 (85.6, 97.3)	88	100 (-)	50	98.0 (86.6, 99.7)	61	96.7 (87.5, 99.2)	10	100 (-)	0.29
Kings College	111	98.2 (92.9, 99.5)	128	99.2 (94.6, 99.9)	133	98.5 (94.1, 99.6)	104	99.0 (93.4, 99.9)	107	99.1 (93.6, 99.9)	10	100 (-)	0.97
Birmingham	117	95.7 (90.0, 98.2)	134	96.3 (91.3, 98.4)	135	99.3 (94.9, 99.9)	96	95.8 (89.3, 98.4)	113	97.3 (92.0, 99.1)	22	100 (-)	0.48
Edinburgh	75	98.7 (90.9, 99.8)	83	96.3 (89.0, 98.8)	45	95.6 (83.4, 98.9)	55	94.4 (83.6, 98.2)	33	100 (-)	11	100 (-)	0.60

		2017/18	1	2018/19		2019/20		2020/21		2021/22		2022/23	
	No at risk	% (95% CI)	No at risk	% (95% CI)	No at risk	% (95% CI)	No at risk	% (95% CI)	No at risk	% (95% Cl)	No at risk	% (95% CI)	Log-rank p-value
Overall	183	98.4 (95.0, 99.5)	176	94.9 (90.4, 97.3)	166	94.6 (89.8, 97.1)	101	98.0 (92.2, 99.5)	175	98.3 (94.8, 99.4)	32	100 (-)	0.11
Type of patient	I		l		I		I				1		1
CLD	120	98.3 (93.5, 99.6)	82	95.1 (87.5, 98.1)	103	97.1 (91.2, 99.1)	65	98.5 (89.6, 99.8)	95	98.9 (92.7, 99.8)	18	100 (-)	0.54
HCC	52	98.1 (87.1, 99.7)	83	95.2 (87.7, 98.2)	58	89.7 (78.4, 95.2)	31	96.6 (77.9, 99.5)	68	100 (-)	10	100 (-)	0.09
VS	9	100 (-)	4	100 (-)	1	100 (-)	2	100 (-)	8	87.5 (38.7, 98.1)	2	100 (-)	0.81
HCC	2	100 (-)	7	85.7 (33.4, 97.9)	4	100 (-)	3	100 (-)	3	100 (-)	2	100 (-)	0.85
downstaging													
ACLF	0	-	0	-	0	-	0	-	1	-	0	-	-
Recipient blood	d group		I		I		I				I		
0	95	97.9 (91.8, 99.5)	78	93.6 (85.3, 97.3)	67	94.0 (84.9, 97.7)	48	95.6 (83.6, 98.9)	80	98.8 (91.5, 99.8)	12	100 (-)	0.41
A	67	98.5 (89.9, 99.8)	71	98.6 (90.4, 99.8)	78	94.9 (86.9, 98.0)	44	100 (-)	72	97.2 (89.3, 99.3)	15	100 (-)	0.47
В	18	100 (-)	20	90.0 (65.6, 97.4)	18	94.4 (66.6, 99.2)	7	100 (-)	22	100 (-)	5	100 (-)	0.45
AB	3	100 (-)	7	85.7 (33.4, 97.9)	3	100 (-)	2	100 (-)	1	100 (-)	0	100 (-)	0.86
Centre	l		I		I		I				I		
Newcastle	4	-	3	-	4	-	2	-	11	-	0	-	-
Leeds	26	96.2 (75.7, 99.4)	20	95.0 (69.5, 99.3)	21	90.5 (67.0, 97.5)	13	100 (-)	14	100 (-)	4	100 (-)	0.71
Cambridge	30	96.7 (78.6, 99.5)	37	97.3 (82.3, 99.6)	31	93.5 (76.6, 98.3)	29	100 (-)	42	95.2 (82.3, 98.8)	5	100 (-)	0.80
Royal Free	13	100 (-)	28	92.9 (74.3, 98.2)	36	94.4 (79.6, 98.6)	11	80.8 (42.3, 94.9)	21	100 (-)	7	100 (-)	0.32
Kings College	46	100 (-)	37	94.6 (80.1, 98.6)	36	97.2 (81.9, 99.6)	30	100 (-)	46	100 (-)	4	100 (-)	0.29
Birmingham	52	98.1 (87.1, 99.7)	38	92.1 (77.5, 97.4)	33	97.0 (80.4, 99.6)	11	100 (-)	25	100 (-)	8	100 (-)	0.46
Edinburgh	12	100 (-)	13	100 (-)	5	80.0 (20.4, 96.9)	5	-	16	93.8 (63.2, 99.1)	4	100 (-)	0.33

- 3.7.4. **Figure 20** shows the unadjusted ninety-day transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first fifty-one months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 90 days.
- 3.7.5. There were no statistically significant differences in the unadjusted ninety-day transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.59 and 0.54).



#### 3.8 ONE-YEAR POST-TRANSPLANT SURVIVAL

- 3.8.1 **Figure 21** shows the unadjusted one-year patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first forty-two months of NLOS. **Table 20** and **Table 21** shows the survival estimates and confidence intervals by blood group and type of patient, for DBD and DCD transplants respectfully. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.
- 3.8.2 For DBD transplants, there was no overall statistically significant difference between the time periods of interest in one-year patient survival (log-rank p-value=0.38). There were no statistically significant differences between the time periods for CLD (log rank p-value≥0.08), blood groups (log-rank p-value≥0.29) and for the individual centres (log-rank p-value≥0.23).
- 3.8.3 For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in one-year patient survival (log-rank p-value=0.52). There were no statistically significant differences between the two time periods for CLD and HCC (log rank p-value≥0.43), blood groups (log rank p-value≥0.36) and for the individual centres (log rank p-value≥0.26).





Table 20	1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 September 2021										
	No at risk on day 0	2017/18 % (95% CI)	No at risk on day 0	2018/19 % (95% CI)	No at risk on day 0	2019/20 % (95% CI)	No at risk on day 0	2020/21 % (95% CI)	No at risk on day 0	2021/22 % (95% CI)	Log- rank p- value
Overall	579	94.6 (92.5, 96.2)	567	94.5 (92.2, 96.1)	555	96.0 (93.9, 97.3)	413	96.2 (93.8, 97.7)	224	92.8 (87.8, 95.8)	0.38
Type of patie	 ht				I		I				ļ
CLD	425	93.9 (91.1, 95.8)	436	94.5 (91.9, 96.3)	423	96.6 (94.4, 98.0)	340	97.2 (94.6, 98.5)	191	93.0 (87.5, 96.1)	0.08
HCC	104	96.1 (89.9, 98.5)	71	92.9 (83.8, 97.0)	80	93.6 (85.3, 97.3)	52	90.4 (78.4, 95.9)	19	91.7 (53.9, 98.8)	0.67
VS	45	97.8 (85.3, 99.7)	55	96.3 (86.0, 99.1)	47	93.6 (81.4, 97.9)	18	94.4 (66.6, 99.2)	11	90.0 (47.3, 98.5)	0.70
HCC	5	-	5	-	5	-	3	-	0	-	-
downstaging											
Recipient blo	ı od aroup		I		1		l				I
0	272	93.7 (90.1, 96.1)	265	93.9 (90.2, 96.2)	241	96.6 (93.4, 98.3)	159	96.8 (92.4, 98.6)	73	91.3 (79.9, 96.4)	0.29
A	224	95.1 (91.3, 97.3)	215	95.8 (92.1, 97.8)	216	94.8 (90.7, 97.1)	182	94.8 (90.2, 97.3)	107	94.1 (85.9, 97.6)	0.98
В	66	97.0 (88.4, 99.2)	53	92.5 (81.1, 97.1)	59	96.6 (87.1, 99.1)	49	98.0 (86.4, 99.7)	26	93.8 (63.2, 99.1)	0.65
AB	17	94.1 (65.0, 99.1)	34	94.0 (78.2, 98.5)	39	97.4 (83.2, 99.6)	23	100 (-)	18	88.9 (62.4, 97.1)	0.47
Centre	1		I		I		I				
Newcastle	26	92.3 (72.6, 98.0)	22	95.5 (71.9, 99.3)	24	91.7 (70.6, 97.8)	24	100 (-)	11	100 (-)	0.59
Leeds	101	91.1 (83.6, 95.3)	59	89.8 (78.6, 95.3)	72	95.5 (86.6, 98.5)	56	94.6 (84.2, 98.2)	26	88.3 (67.9, 96.1)	0.49
Cambridge	67	95.5 (86.8, 98.5)	61	100 (-)	58	93.1 (82.6, 97.3)	28	100 (-)	28	94.7 (68.1, 99.2)	0.23
Royal Free	82	95.1 (87.5, 98.1)	80	91.3 (82.5, 95.7)	88	96.5 (89.5, 98.8)	50	98.0 (86.6, 99.7)	29	93.1 (75.1, 98.2)	0.40
Kings	111	98.2 (92.9, 99.5)	128	96.8 (91.7, 98.8)	133	98.5 (94.1, 99.6)	104	95.6 (88.5, 98.3)	59	96.1 (85.2, 99.0)	0.69
College		. ,		. ,		. ,		. ,			
Birmingham	117	93.2 (86.8, 96.5)	134	94.8 (89.3, 97.5)	135	95.5 (90.2, 97.9)	96	95.8 (89.3, 98.4)	53	90.1 (77.8, 95.8)	0.60
Edinburgh	75	96.0 (88.1, 98.7)	83	92.6 (84.3, 96.6)	45	95.6 (83.4, 98.9)	55	94.1 (82.8, 98.1)	18	100 (-)	0.76

	No at risk	2017/18 % (95% CI)	No at risk	2018/19 % (95% CI)	No at risk	2019/20 % (95% CI)	No at risk	2020/21 % (95% CI)	No at risk	2021/22 % (95% CI)	Log-rank p value
Overall	183	95.6 (91.4, 97.8)	176	92.6 (87.5, 95.6)	166	92.7 (87.6, 95.8)	101	94.6 (87.4, 97.7)	83	96.9 (87.9, 99.2)	0.52
Type of patie	nt		1		l						l
CLD	120	96.7 (91.3, 98.7)	82	92.7 (84.4, 96.6)	103	95.1 (88.6, 97.9)	65	95.1 (85.6, 98.4)	42	96.4 (77.2, 99.5)	0.73
HCC	52	92.2 (80.5, 97.0)	83	92.7 (84.4, 96.6)	58	87.9 (76.3, 94.1)	31	92.7 (73.7, 98.2)	35	100 (-)	0.43
VS	9	-	4	-	1	-	2	-	4	-	-
HCC downstaging	2	100 (-)	7	85.7 (33.4, 97.9)	4	100 (-)	3	100 (-)	1	100 (-)	0.84
Recipient blo	l ood gro	oup	I		I		I		l		I
0	95	96.8 (90.5, 99.0)	78	92.3 (83.6, 96.4)	67	94.0 (84.9, 97.7)	48	95.6 (83.6, 98.9)	42	100 (-)	0.36
A	67	95.4 (86.5, 98.5)	71	95.7 (87.4, 98.6)	78	90.9 (81.9, 95.6)	44	95.2 (81.9, 98.8)	28	96.4 (77.2, 99.5)	0.69
В	18	94.4 (66.6, 99.2)	20	90 (65.6, 97.4)	18	94.4 (66.6, 99.2)	7	85.7 (33.4, 97.9)	13	87.5 (38.7, 98.1)	0.94
AB	3	66.7 (5.4, 94.5)	7	71.4 (25.8, 92.0)	3	100 (-)	2	100 (-)	0	100 (-)	0.64
Centre	1		1								
Newcastle	4	-	3	-	4	-	2	-	6	-	-
Leeds	26	92.3 (72.6, 98.0)	20	89.7 (64.8, 97.3)	21	85.4 (61.3, 95.1)	13	100 (-)	6	100 (-)	0.70
Cambridge	30	96.7 (78.6, 99.5)	37	94.6 (80.1, 98.6)	31	90.3 (72.9, 96.8)	29	100 (-)	19	100 (-)	0.33
Royal Free	13	92.3 (56.6, 98.9)	28	85.7 (66.3, 94.4)	36	91.6 (76.1, 97.2)	11	69.3 (31.2, 89.1)	10	66.7 (5.4, 94.5)	0.35
Kings College	46	95.5 (83.0, 98.8)	37	94.6 (80.1, 98.6)	36	97.2 (81.9, 99.6)	30	91.7 (70.2, 97.9)	23	100 (-)	0.80
Birmingham	52	96.2 (85.5, 99.0)	38	92.1 (77.5, 97.4)	33	97.0 (80.4, 99.6)	11	100 (-)	10	100 (-)	0.68
Edinburgh	12	100 (-)	13	100 (-)	5	80 (20.4, 96.9)	5	100 (-)	9	88.9 (43.3, 98.4)	0.26

- 3.8.4 **Figure 22** shows the unadjusted one-year transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first forty-two months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 1 year.
- 3.8.5 There were no statistically significant differences in the unadjusted one-year transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.68 and 0.72).



## 4 CONCLUSIONS

The new National Liver Offering Scheme was implemented on the 20<sup>th</sup> March 2018. 3975 DBD and 3896 DCD livers were offered for transplantation in the first fifty-four months of the scheme. Of the DBD livers offered, 3456 (87%) were retrieved for the purposes of transplantation and 2993 (87%) were transplanted (all but 26 were transplanted in the UK).


Rhiannon Taylor, Maria Jacobs and Suzie Phillips Statistics and Clinical Research

September 2022


#### APPENDIX A: SUPER-URGENT CATEGORIES


#### INDICATION FOR REGISTRATION


- Category 1: Aetiology: Paracetamol poisoning: pH <7.25 more than 24 hours after overdose and after fluid resuscitation
- 2 Category 2: Aetiology: Paracetamol poisoning: Co-existing prothombin time >100 seconds or INR >6.5, and serum creatinine >300 µmol/l or anuria, and grade 3-4 encephalopathy
- 3 Category 3: Aetiology: Paracetamol poisoning: Significant liver injury and coagulopathy following exclusion of other causes of hyperlactatemia (e.g. pancreatitis, intestinal ischemia) after adequate fluid resuscitation: arterial lactate >5 mmol/l on admission and >4 mmol/l 24 hours later in the presence of clinical hepatic encephalopathy
- 4 Category 4: Aetiology: Paracetamol poisoning: Two of the three criteria from category 2 with clinical evidence of deterioration (eg increased ICP, FiO<sub>2</sub> >50%, increasing inotrope requirements) in the absence of clinical sepsis
- 5 Category 5: Aetiology: Favourable non-paracetamol aetiologies such as acute viral hepatitis or ecstacy/ cocaine induced ALF: the presence of clinical hepatic encephalopathy is mandatory and: prothrombin time >100 seconds, or INR >6.5, or any three from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; any grade of hepatic encephalopathy with jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 6 Category 6: Aetiology: Unfavourable non-paracetamol aetiologies such as seronegative or idiosyncratic drug reactions: a) prothrombin time >100 seconds, or INR >6.5, or b) in the absence of clinical hepatic encephalopathy then INR >2 after vitamin K repletion is mandatory and any two from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; if hepatic encephalopathy is present then jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 7 Category 7: Aetiology: Acute presentation of Wilson's disease or Budd-Chiari syndrome. A combination of coagulopathy and any grade of encephalopathy
- 8 Category 8: Hepatic artery thrombosis on days 0 to 21 after liver transplantation
- 9 Category 9: Early graft dysfunction on days 0 to 7 after liver transplantation with at least two of the following: AST >10,000; INR >3.0; arterial lactate >3 mmol/l; absence of bile production
- 10 Category 10: The total absence of liver function (eg after total hepatectomy)
- 11 Category 11: Any patient who has been a live liver donor (NHS entitled) who develops severe liver failure within 4 weeks of the donor operation
- 20 Category 20: Acute liver failure in children under two years of age: INR >4 or grade 3-4 encephalopathy. Definition: Multisystem disorder in which severe acute impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis in a child with no recognised underlying chronic liver disease. Children with leukaemia/lymphoma, haemophagocytosis and disseminated intra-vascular coagulopathy are excluded



#### APPENDIX B: SIX MONTH REGISTRATION OUTCOME







63